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ABBREVIATIONS
A1 = The A1 chain of cholera toxin
AC = adenylate cyclase
ADP = adenosine diphosphate
ADP-ribose = adenosine diphosphoribose
AGG's = agglutinogens
AMP = adeno sine monophosphate
cAMP = cyclic adenosine monophosphate
ATP = adenosine triphosphate
A599 = [ 12-(phenyl methyl amino)dodecanyl] guanidine
A603 = [10-(acetyl amino)decanyl] guanidine
B S A = bovine serum albumin
CaM = calmodulin
CAMR = Centre for Applied Microbiology and Research
CD = circular dichroism
CHAPS = 3-[(3-cholamidopropyl)dimethylammonia]propansulfonuW
CLtlC * imvuWmvx o\ ^ t\tC0
CHO = Chinese hamster ovary
Cys = cysteine
CxWuoV
DSP = dithioois (succinimidyl propionate)
DST = disuccinimidyl tartarate
DTT = dithiothreitol
E. coli = Eschericia coli
EDTA = ethylene diamine tetra acetic acid
II
E F - 2 = elongation factor 2
ELISA = enzyme linked immunosorbant assay
FHA = filamentous haemagglutinin
FPLC = fast protein liquid chromatography
G AB A = gamma amin obutyric acid
GlcNAc = N-acetyl glucosamine
GMP = guanosine monophosphate
cGMP = cyclic guanosine monophosphate
Gmi = galactosyl-N-acetyl glucosamine-[N acetyl neuraminyl]-
galactosylglucosyl-ceramide
G i = inhibitory regulatory unit of adenylate cyclase
G s = stimulatory regulatory unit of adenylate cyclase
Gproteins = GTP-binding proteins
GTP = guanosine monophosphate
HLT = heat-labile toxin
HPLC = high pressure liquid chromatography
KDO = 3-deoxy-2 octulosonic acid
kcat = catalytic capacity
Kd = dissociation constant
Km = Michaelis constant
LPS = lipopolysaccharide endotoxin
MeCD = 2,6-0 dimethyl p-cyclodextrin
NAD+ nicotinamide adenine dinucleotide
Neu Ac = N-acetyl neuraminic acid
Neu Ac Gal P-Glc N Ac = N-acetyl neuramic acid galactose p-4 N-
acetyl glucosamine
OD = optical density
PBS = phosphate buffered saline
UvUovvkovu Wt,
Ri = inhibitory receptor of adenylate cyclase
R s = stimulatory receptor of adenylate cyclase
S D S Pf\QE = sodium dodecyl sulphate polyacrylamide gel
electrophoresis
TCT = trachael cytotoxin
Trp = tryptophan
Vmax maximum catalytic capacity of the enzyme
Pertussis toxin is the most complex of the bacterial toxins discovered to date. It
has an estimated molecular weight of 117000 and catalyses the ADP-ribosylation of a
regulatory protein of adenylate cyclase, Gi, preventing hormonal inhibition of cyclase
activity resulting in a build-up of intracellular cAMP levels. As Gi is notoriously
difficult to isolate and very labile, the toxin catalysed NAD+-glycohydrolase is routinely
used as a measure of its activity. A Km of 27|iM for NAD+ was obtained for this
reaction. The use of reducing reagents is essential within this assay procedure as
reduction of an internal disulphide bond is required for enzymic activity. 250mM
reducing reagent resulted in maximum activity, a concentration which appeared very
high if the reagent is only required for activation. The sulphydryl containing reagent
were shown to be both essential for enzymic activity and were also substrates for the
reaction. An ADP-ribosyl-cysteine reaction product has been isolated. A Michaelis
constant of 105mM was obtained for cysteine acting as a substrate in saturating NAD+.
Binding of NAD+ to pertussis toxin was investigated by both equilibrium
dialysis and quenching of the toxins intrinsic fluorescence on titration with NAD+.
Equilibrium dissociation constants, Kd values, were obtained at a number of different
temperatures by equilibrium dialysis and a value of 57kJoules mol~ * was derived for the
enthalpy change on binding of substrate to protein, a value typical of such an interaction.
The number of binding sites on the toxin for NAD+ was shown to be one. Equilibrium
dialysis was carried out in a urea solution in order to obtain sufficiently high protein
concentrations to minimise error. Urea, at the concentration used, was shown to have
no effect on the tertiary structure of the toxin by circular dichroism and as such should
not affect the binding of ligand to protein. The results from equilibrium dialysis and
fluorescence were in close agreement and correlated well with the Km value obtained for
the toxin catalysed NAD+-glycohydrolase activity.
The association of the toxin subunits in space and its overall stoichoimetry were
investigated using reversible cross-linkir^reagents, two-dimensional gel electrophoresis
and Western blotting. The results obtained suggest that S-4 is in close association with
subunits S-2 and S-3, providing further evidence for the existence of two dimers within
the holotoxin, and show that S-l is within close proximity of subunits S-2 and S-3.
The latter suggests that S-l is on a plane above the B-digomer subunits, in the same
way as has been proposed for cholera toxin. No cross-links have so far been obtained
involving S-5 indicating that the other subunitamay surround this connecting peptide in
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1.1 Pertussis the disease
Pertussis, or as it is more commonly known "whooping cough", is
an acute disease of the human respiratory tract, the symptoms of which are most
severe in young children. The disease has been clinically recognised since the 16th
century, with the first published account of symptoms being in 1640. Pertussis was a
major cause of childhood morbidity and mortality until the gradual introduction of
mass immunisation from the late 1940's, with most children being immunised from
about 1957. This vaccination programme dramatically reduced the incidents of
whooping cough in the following decades, but recently, owing to the much publicised
possibility of side-effects, uptake rates of this vaccine have decreased because of a
decline in the public's confidence with the vaccine to it. This has led to two recent
epidemics of the disease in the U.K., one in 1979 and the other in 1982. The
acceptance rate is now back to about 70% and the disease is less common, but the
constant threat of another epidemic illustrates the need for a new vaccine which would
hopefully reduce the possibility of side effects (Robinson et al 1985).
Pertussis exists worldwide and is still today a major problem in Third World
countries where 0.5-1 x It)** cases are reported each year. The disease is transmitted by
droplet infection and there is a cyclical pattern of disease occurring every three to five
years (Fine and Clarkson, 1982) as is also the case with the diseases measles and
rubella.
The disease can be sub-divided into three symptomatic stages (Friedman,
1988), these being the catarrhal, paroxysmal and convalescent stages. The bacteria
must first colonise the ciliated epithelium of the upper respiratory tract and this initial
incubation period can last from six to twenty days (Manclark, 1976). Once the host
tissue has been colonised the symptoms of the catarrhal stage manifest. These are
similar to a mild cold with some associated inflammation of the nose and throat
mucous membranes. As this stage of the disease progresses the patient begins to
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suffer bouts of coughing which increase in severity with time, the bouts becoming
more spasmodic as the disease enters the paroxysmal stage. Initially coughing is more
frequent at night, but as the final stage of the disease progresses the bouts are more
prevalent during the day. A child may suffer fifteen to twenty five bouts of
paroxysmal coughing each day at the height of the disease (Manclark and Cowell,
1984). The child must concentrate all of its energy on clearing the air-passages of
mucous and with each successive coughing bout the effects become more violent. The
characteristic "whoop" occurs as a result of the child finally clearing the lungs of
mucous and rapidly inspiring air into the lungs through the swollen glottis. Pertussis,
meaning severe cough, is a much better term for describing the disease as the patient
does not whoop with every bout of coughing (Wilson et al 1965; Zoumboulakis et al
1973).
Many complications can occur during this acute stage of the disease, including
conjunctival haemorrhage, haemorrhage of the neck and shoulders, herniae,
emphysema, prolapsed rectum and pneumothorax. The most dangerous
complications, however, are associated with secondary bacterial infections. The
mortality rate of pertussis is greatest in children less than one year old with the major
cause of death being as a consequence of secondary infection (Miller and Fletcher,
1976).
1.1.2. Bordetella pertussis
The bacterium responsible for the disease pertussis is Bordetella pertussis. The
bacteria are gram-negative cocobacilli and were first isolated in 1906 by Bordet and
Gengou from an infected patient (Bordet and Gengou, 1906). The organism is a
human pathogen and is found only on the ciliated epithelium of the human upper
respiratory tract (Mallory and Horner, 1912). There are four species in the genus
Bordetella; Bordetella pertussis and Bordetella parapertussis which are both human
pathogens, Bordetella bronchisceptica which is an animal pathogen and Bordetella
avium which infects birds. All four are non-invasive respiratory tract parasites which
share certain characteristics and cause similar disease in their host species.
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Bordetella pertussis produces many biologically active substances, some of
which may play a part in the disease process. However, the precise role of each of
these virulence factors in the pathogenesis of disease is still under a great deal of
investigation (Munoz and Bergman, 1979; Wardlaw and Parton, 1983). One of these
proteins, pertussis toxin, which is the protein of interest in this project, may be the
major virulence factor produced by the bacteria (Pittman, 1979; Sekura et al ^1983:
Nicosia and Rappuoli, 1987; Gross etal } 19891. Whether all of the symptoms of
pertussis result from the activity of this single exotoxin is a matter of much
controversy.
1.1.3. Treatment and control
B. pertussis is sensitive to several antibiotics, but their use is limited after the
onset of the catarrhal stage of the disease. These antibiotics include erythromycin,
chloramphenicol and tetracycline, with chloramphenicol being the antibiotic generally
used in treatment as it is both safe and effective to use in children (Bass et al ,1969;
Islur et al 19751. The treatment of pertussis with antibiotics has no effect upon the
course of the disease, but they may reduce the time during which the host is infectious
and may also help in the treatment of secondary bacterial infections (Baraff et al
1978).
The vaccines currently used for the prevention of pertussis in most countries are
suspensions of killed, whole-cells of B. pertussis (Robinson et al. 1985). These
vaccines have been the cause of much public concern due to the rare number (1 in
100,000 at most) of associated cases of brain damage. However, it is true to say that
the advantages of pertussis vaccination are far greater than any of the risks associated
with it. In France, for example, where a vaccine of similar composition to that used in
the U.K. is administered, there is very little debate on the risk of pertussis vaccination.
It is estimated that 95% of children are immunised against whooping cough and this
high vaccine uptake rate is reflected in the lack of a recent epidemic of whooping
cough in this country (Miller et al ,1982).
The major concern of pertussis research in recent years has been the
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development of a new acellular vaccine. Acellular vaccines have been developed in
Japan and have been in use there for several years. The current, or shortly available
vaccines range from pure detoxified pertussis toxin (Sekura et al. 1986') through
filamentous haemagglutinin/pertussis toxin vaccines (Sato etal 19841 to a filamentous
haemagglutinin-pertussis toxin - agglutinogen vaccine (Robinson et al,, 19851. with
each of these vaccine constituents being detoxified proteins produced by B. pertussis.
In view of this a great deal of work has concentrated on the purification and
characterisation of the biologically active substances produced by the bacteria.
The next stage in acellular vaccine production should involve the isolation of
subunits, peptide fragments or the preparation of synthetic peptides which contain
epitopes essential to induce a protective immune response in children (Robinson and
Ashworth, 1988). Much research is presently concentrated on production of the above
with the continued aim of producing vaccine components which are immunogenic but
non-toxic.
1.2. Biological active substances produced by B. pertussis
1.2.1. Agglutinogens
There are a total of fourteen agglutinogens produced by all species within the
genus Bordetella, with B. pertussis expressing seven of them in various combinations
on different strains. Agglutinogens are surface antigens which can stimulate the
production of antibodies which in turn cause bacterial cell agglutination (Robinson et
al ,1985). They are proteins of molecular masses ranging within 10 000 - 23 000.
AGG's 1, 2 and 3 are the major agglutinogens and 4, 5 and 6 are minor antigens. The
biochemical nature of the agglutinogens are summarised in Table. 1.1.
AGG 1 occurs on all strains of B. pertussis. The nature of this protein has not
been determined, but it does not appear to be a fimbrial protein. AGG's 2 and 3 are
fimbrial proteins of molecular mass 22 500 (Livey etal. 1987) and 22 000 (Amelina et
ah, 1976) respectively. The amino acid sequences of AGG's 2 and 3 have been
determined and they exhibit 60% sequence homology. AGG's 4, 5 and 6 are minor
antigens and are apparently associated with either AGG 2 or 3.
TABLE 1.1 Agglutinogens of Bordetella pertussis
Agglutinogen Species Serotype Biochemical
Specificity Specificity Structure
B. pertussis All strains Unknown
Outer-membrane
protein?
B. pertussis 1.2.0; 1.2.3 Fimbrial protein
22.5kDa subunit
B. pertussis 1.0.3; 1.2.3 Fimbrial protein
22 kDa subunit
B. pertussis Minor associated Unknown
with AGG2
B. pertussis Minor associated Unknown
with AGG2
B. pertussis Minor associated Unknown
with AGG3
7 B. pertussis All strains Unknown
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It has been proposedby Robinson etal..( 19891 that these minor structures may
represent minor epitopes in association with the main fimbrial structural subunits, or,
on the other hand, that they may perhaps be minor fimbrial proteins other than these
repeating structural subunits.
The importance of the agglutinogens in pertussis immunity was demonstrated
by the MRC clinical trials of whole-cell pertussis vaccines when the agglutinin
response to vaccines was shown to correlate with their protection in children (MRC
Report, 1959). The CAMR acellular vaccine consists of equal amounts of separately
purified pertussis toxin, filamentous haemagglutinin and AGG's 2 and 3 (10pg/dose).
Each component is separately formaldehyde treated and then combined and adsorbed
on an aluminium adjuvant (Robinson et al 1986). The AGG's are isolated from cells
by homogenisation and repeated ammonium sulphate precipitation with AGG's 2 and
3 being present in the ratio of 3-2 respectively within the vaccine.
1.2.2. Filamentous haemagglutinin
Filamentous haemagglutinin (FHA) is a protein which has been shown by
electron microscopy to be a filamentous structure of 2nm in diameter and 40-100nm in
length (Arai and Sato, 1976; Morse and Morse, 1976). It was originally thought that
FHA was derived from bacterial surface fimbria (Sato et al. ,1979) and was known as
filamentous and fimbrial-haemagglutinin. Recent evidence has shown this not to be
true as both the amount of FHA did not correlate with the number of fimbriae and that
fimbriae could not be labelled with antibodies ot FHA (Ashworth et al. 1982).
Purified FHA is a heterogeneous mixture of polypeptides of Mr 90 000 - 220
000 (Irons etal.T983). The degree of heterogeneity is dependent on the strain used
and the growth conditions. Filamentous haemaglutinin is one of the two
haemagglutinins secreted by B. pertussis, pertussis toxin being the other. Both of
these proteins have very distinct chemical and biological properties. Antibodies
against FHA inhibit the adhesion of B. pertussis to mammalian cells (Sato etaLf1974:
Sato et al.. ,1979) demonstrating that this protein must be important in 3 Vkvnq
bacteria to host cells.
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1.2.3. Adenylate cyclase
Bordetella pertussis adenylate cyclase is extracytoplasmic and several strains of
the bacteria release considerable amounts of this protein into the culture medium
(Hewlett et 81^19761. The enzyme is activated by eukaryote calmodulin and leads to
the uncontrolled production of cAMP (Confer and Eaton, (1982). Many of the
symptoms of whooping cough infection are due to an impaired immune response by
the host. These symptoms are the lack of fever, an inadequate neutrophillic response
and high incidence of bacterial secondary infections. Adenylate cyclase is responsible
for these disease characteristics as the high levels of cAMP produced impair the ability
of polymorphonuclear leukocytes and macrophages for chemotaxis, phagocytosis,
superoxide generation and microbial killing. Adenylate cyclase has been shown to be
essential in virulence as an insertion mutant deficient in AC was avirulent in an
animal model of pertussis infection (Weiss et al.,1983) and introduction of a cloned
AC gene into this mutant restored virulence (Brownlie et aL 1988).
The adenylate cyclase gene has been cloned and sequenced (Glaser et aL 1988)
and it has the potential to encode for a protein of 200kDA.
The gene is shown in Figure 1.
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The 200kDa form of the protein is required for penetration (Hewlett etal. 1988)
suggesting that the observed proteolytic cleavage of the 200kDa active form to a
smaller 45kDA form which is non-toxic is irrelevant for both the secretion and
production of a toxic form of the enzyme.
The protein penetrates the host cell directly from the cytoplasm and produces a
transient increase in host-cell cAMP levels, the mechanism of cAMP production being
shown in Fig. 1.2. This is contrasted by the toxins which act through ADP-
ribosylation, which is a long-lasting effect. This suggests that the initial rise in host
cell cAMP produced by AC is amplified by the increased production of cAMP by the
latent ADP-ribosylation.
The adenylate cyclase can also act as a haemolysin. The 1250 C-terminal amino
acids have a significant degree of homology with the E. coli a-hemolysin and the
hemolysin of pasteurella hemoljtica (Glasser et al^ 1988) with the homology being
particularly pronounced between residues 640 and 910. However the relationship
between the toxic and haemolytic activities of the enzyme remains to be clarified.
1.2.4. Lipopolysaccharide endotoxin
There are two lipopolysaccharides produced by B. pertussis, LPS I and LPS II,
each containing low molecular weight polysaccharides. LPS I contains a non-
phosphorylated 3-deoxy-2,octulosonic acid (KDO) and LPS II contains
phosphorylated KDO. Bacterial lipopolysaccharide endotoxins have the general
structure shown in Fig. 1.3.
Milner et aH^ 619631 showed that B. pertussis LPS are long fibres of 7-8nm in
diameter and are found either as loops or rings. By SDS polyacrylamide gel
electrophoresis a mass of 5^000 has been calculated for this endotoxin (Peppier,
1984). LPS does not appear to play an important role in the pathogenesis of the
disease; however, it is thought that some of the unpleasant, though mild, side-effects
associated with pertussis whole-cell vaccination may be a result of this endotoxin.





1.2.5. Dermonecrotizing (heat-labile) toxin
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Heat-labile toxin (HLT) is a 56°C-labile protein. The protein is also known as
dermonecrotizing toxin as it causes skin lesions. First discovered in 1909 by Bordet
and Gengou, it is thought to be responsible for the changes in the respiratory tract
mucosa typical of B. pertussis infection. HLT has an overall molecular mass of 102 000
and is composed of four subunits - two of 20(000 and the other two of 30/000
(Endoh etal.} 1986).
The role of HLT in the pathogenesis of pertussis is again unclear, but recent
evidence shows that the toxin's vasoconstrictive effects play a significant part in the
initial stages of the disease. This HLT-induced vasoconstriction could result in both
respiratory and peripheral circulatory failure leading to the decipediosijand petichial
haemorrhage seen in HLT innoculated guinea-pig skin (Parton, 1986).
1.2.6. Trachael cytotoxin
Trachael cytotoxin is the only toxin produced by B. pertussis which has been
shown to play a direct role in damaging the respiratory tract. Purified TCT can be
shown to produce the ciliostasis and the specific ciliated cell-damage found in B.
pertussis infection (Goldman etal,,1982).
This toxin is a small glycopeptide probably derived from the peptidoglycans of
the cell envelope. Its estimated molecular weight is between 1,235 and 1^400. TCT
appears to be released from B. pertussis by hydrolysis of peptidoglycan fragments
from the peptidoglycan matrix of the bacteria itself and not by release from
peptidoglyclan precursors.













































































































































1.3. The Structure and Function of Pertussis Toxin
1.3.1. Introduction
In 1979, Pittman suggested that all of the harmful effects of B. pertussis
infection are as a consequence of one specific antigen. Other diseases, such as
tetanus and diphtheria, have this characteristic where tetanus toxin and diphtheria toxin
respectively are responsible for the harmful effects of tetanus and diphtheria. If this is
the case for pertussis then it has been suggested (Pittman, 1979) that pertussis toxin
could be this antigen. As is shown in Table 1.4 pertussis toxin is involved in each
stage of the disease after exposure of the host to the bacteria. Pertussis results as a
consequence of the bacteria adhering to certain cell types, a process which involves a
number of virulence factors, followed by the secretion of a number of toxins. It
seems unlikely that pertussis is caused by a single exotoxin as B. bronchiseptica
causes a pertussis-like disease in animals (kennel cough) and B. parapertussis
produces a mild form of whooping cough and neither produce pertussis toxin or a
pertussis toxin-like protein. Pertussis toxin cannot be administered to children but if
this was done the patient would probably not get whooping cough, adding to the
evidence against pertussis being a disease mainly caused by one toxin.
Pertussis toxin exhibits a wide number of biological activities, the most
important of which is the activation of mammalian adenylate cyclase. The
manifestations of the effects of perussis toxin in many animals include promotion of
lymphocytosis and leukocytosis, haemagglutination, <bf\.Vxw<i5 susceptibility to
histamine, serotonin, endotoxin and cold, enhancing insulin secretion from pancreatic
cells, inducing hypoglycaemia, inhibiting adrenalin induced hyperglycaemia and
associated adjuvancy effects, especially for IgE. (For review see Wardlaw and
Parton, 1983). However, it was demonstrated by Irons and MacLennan (1979) that
purified pertussis toxin did not retain all of the biological activities shown above - only
some of them, suggesting that the others may be as a result of contamination with
other proteins.
As a consequence of these diverse biological activities the toxin was given a









































































lymphocytosis promoting factor, islet-activating protein, histamine sensitisation factor,
pertussigen and finally pertussis toxin. Pertussis toxin is now the name universally
accepted, which may not be completely appropriate in view of the other toxins of the
bacteria.
1.3.2. The structure of pertussis toxin
In recent years the reported molecular masses of pertussis toxin have been
variable, with values ranging from 171 kDA (Cowell et aL^ 19821 down to lOOkDA
(Morse and Morse, 1976). The molecular mass of 117kDa calculated by Tamura et al.^
(1982) is the only precise result. The method used was analytical ultracentrifugation.
They found that pertussis toxin was homogeneous in 2M urea at acid pH, had a
sedimentation coefficient of 6.6S and molecular mass of 117 kDA as measured by
sed (mentation equilibrium at two vector speeds. A summary of the molecular mass
values are shown in Table 1.4.
The toxin is a very stable protein, the holotoxin being resistant to proteases
(Peppier et al.T985) although susceptibility to the action of protease increases as the
holotoxin dissociates into subunits. The toxin retains its biological activity in
solutions containing 2M urea, but as the concentration increases, biological activity is
lost as the toxin dissociates (Tamura et al., 1982).
The toxin has been shown by SDS polyacrylamide gel electrophoresis (SDS
PAGE) to be composed of five different subunits termed S-l to S-5 on the
basis of their decreasing molecular mass. Tamura et al.^, (1982) showed via
dens itometric analysis of Coomassie blue stained pertussis toxin subunits that the
molar ratio of the subunt s S-l, S-2, S-3, S-4 and S-5 within the holotoxin was
1:1:1:2:1. They calibrated for each subunit the relationship between pg of subunit
and Coomassie blue staining. This molar ratio was also demonstrated by Sekura et al,
(1983) by a similar procedure. Rappuoli and co-workers (1987) further confirmed
this subunit stoichiometry, their evidence being based on the association of the toxin
subunits in different urea concentrations. Although this stoichiometry has been


















































































































































stained gels is based on the assumption that all proteins have the same capacity for dye
binding, and the association of subunits in dissociating agents does not directly
demonstrate the stoichiometry of the protein. This stoichiometry might be confirmed
by ultracentrifugation of the holotoxin and isolated subunits. Chemical cross-linking
reagents would also be invaluable in confirming this proposed stoichiometry.
The overall subunit arrangement of pertussis toxin is similar to that of many
other bacterial exotoxins in that it has the typical A-B type structure (Gill, 1976; van
Heyningen, 1982; Bums and Manclark, 1985; Burns, 1988). The A-protomer is
enzymically active and is composed of S-l alone. The binding, B-oligomer is
involved in receptor binding and intemalisation of the S-l subunit. This part of the
toxin is made up of the remaining subunits. The proposed stoichiometry of toxin
subunits is shown in Fig. 1.4. If the holotoxin is exposed to 2M urea S-l will
dissociate from the B-oligomer. Further exposure of the B-oligomer to 5M urea
causes the binding component to dissociate into two dimers of S-2 and S-4 (Dl) and
of S-3 and S-4 (D2) and a free S-5. Finally exposure to 8M urea causes the two
dimers to dissociate into their constituent subunts (Rappuoli and Silvestri, 1987).
Montecucco et al. ,(19861. using the technique of hydrophobic photolabelling of
pertussis toxin subunits, suggested a model for the spatial organisation of the
subunits. This technique involves the use of radioactive, photoreactive, phospholipid
analogues which were interdispersed among detergent miceles. These phospholipid
analogues can cross-link to the protein thereby showing the toxin's detergent-binding
sites. This approach is very sensitive and can be used to map the hydrophobic regions
on the protein which are involved in interaction with lipids. They showed that
subunits S-2, S-3, S-4 and S-5 probably all interacted with lipid, suggesting that each
of these subunits is involved in membrane insertion of the toxin. Subunits S-2 and S-
3 were shown to penetrate the hydrophobic core of the micelle and subunit S-4 was
found at the polar head-group region of the phospholipids. S-l was not labelled in
this model suggesting that the B-oligomer may shield S-l from interacting with lipids.
The model proposed is shown in Fig. 1.5.
This proposed pentameric binding domain, the B-oligomer, shows many
similarities with the proposed structure of cholera toxin where five identical B-
PROPOSED SUBUNIT STOICHIOMETRY OF
PERTUSSIS TOXIN, ADAPTED FROM
RAPPUOLI AND SILVESTRI (1987)
 
FIGURE 1.5
INTERACTION OF THE B-OLIGOMER SUBUNITS WITH THE
HOST-CELL PLASMA-MEMBRANE.
ADAPTED FROM MONTECUCCO ETAL/1986)
IIDd IDd
20
subunits are arranged around the A-subunit, which sits above the plane of the binding
component (van Heyningen, 1977). The S-l subunit of pertussis toxin may occupy a
similar position, but this has not yet been established. Work with reversible cross-
linking reagents of different molecular spans should help to clarify this proposed
structure. This work was undertaken in this project and the results obtained shown in
Chapter 6.
1.3.3. Molecular cloning of pertussis toxin genes and its
primary structure
The complete amino acid sequence of all the toxin subunits have been derived
from the nucleotide sequences (Locht and Keith, 1986; Nicosia et al.t 1986). The
calculated molecular masses of the mature subunits are S-l 26 024 ; 21 924 for S-2;
21 873 for S-3; 12 058 for S-4 and 11 013 for S-5 (Locht and Keith, 1986). The S-l
subunit contains 234 amino acids, S-2 and S-3 both contain 199 amino acids, S-4
contains 110 amino acids and 100 amino acids for S-5. From the proposed
stoichiometry discussed above, that is two molecules of S-4 per molecule of toxin, the
overall calculated molecular mass is 104 950. This is in comparison with the value of
117 000 derived from analytical ultracentrifugation (Tamura et al. 1982), this
discrepancy of 12 000 may be due to the existence of another subunit within this
model.
The genes encoding all of the subunits are located within a 3.2Kbase segment
of the bacterial genome (Locht and Keith 1986; Nicosia et al. 1986). The gene coding
for S-4 overlaps that of S-2 and S-5 (see Fig. 1.6). The arrangement of the five genes
are typical of a bacterial operon in that the genes are flanked by a promotor region and
a termination signal is found downstream from the five genes (Rappuoli and Silvestri,
1987). Upstream of the promotor is a piece of DNA which is the target for a trans-
activating protein (vir). This protein is responsible for switching on and off
transcription of the pertussis toxin subunits and other virulence genes.
Each of the five subunits are synthesised as precursor proteins with a preceding
signal peptide, as would be expected for a secreted protein. This suggests that each of
FIGURE 1.6
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the subunits ^ synthesised individually, whereupon they are secreted into the
periplasm where their signal peptides are cleaved and the mature subunits assembled
into the holotoxin. Once assembled in the periplasm, the toxin is released into the
extracellular medium (Nicosia et aL 1986; Nicosia and Rappuoli, 1987).
There is a very high degree of homology between subunits S-2 and S-3. The
two subunits show 70% amino acid homology and 75% homology at the DNA level.
This homology suggests that the two genes were generated from a gene duplication of
one ancestral gene, which have subsequently undergone mutations leading to the
production of two individual subunits. This high degree of similarity is reflected in
both the secondary structure of the two subunits and also in their hydrophilicibt)
however, as shown by Tamura et al. (1989) one subunit cannot substitute for the
other in the enzymically active toxin.
The amino acid sequence of the S-l subunit has been compared to the active
subunits of many other bacterial exotoxins. Two regions of significant homology can
be identified between pertussis toxin and both cholera and Escherichia, coli heat-labile
toxins. These regions of homology are seen at analogous regions within all three
toxins.
Region 1
Pertussis S-l subunit 8 Tyr Arg Tyr Asp Ser Arg Pro Pro 15
Cholera A-subunit 6 Tyr Arg Ala Asp Ser Arg Pro Pro
E. coli LT A-subunit 6 Tyr Arg Ala Asp Ser Arg Pro Pro
Retrion 2
Pertussis S-l subunit 51 Val Ser Thr Ser Ser Ser Arg Arg 58
Cholera A-subunit 60 Val Ser Thr Ser Leu Ser Leu Arg 67
E. coli LT A-subunit 60 Val Ser Thr Ser Leu Ser Leu Arg 67
These similarities at the amino acid level are not reflected in the primary
sequence as pertussis toxin uses different triplet codons to that of cholera toxin and LT
toxin. No other sequence homologies could be found between pertussis toxin S-l
subunit and the other two A-subunits. The DNA sequences of the other pertussis
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toxin subunits show no resemblance to any of the other ADP-ribosylating toxins.
1.3.4. The role of each subunit
The B-oligomer of pertussis toxin is responsible for binding of the toxin to a
specific receptor on the host cell surface and also facilitates the entry of the S-l subunit
into the cell. The B-oligomer has been shown to bind to a 165kDa glycoprotein on
Chinese hamster ovary cells (CHO cells) (Brennan et al.^ 1988; Burns, 1988). The
glycoprotein has been termed an N-acetylneuraminic acid Galactose (3-4 N-
acetylglucosamine (Neu Ac Gal (3 Glc N Ac) oligosaccharide sequence suggesting
that this carbohydrate may be important in the binding of toxin to host cells. The S-l
subunit does not interact with the cell membrane (Montecucco et al.; 1986) and the
mechanism whereby it enters the cell is unknown (see below). Once within the cell
the S-l subunit activates adenylate cyclase by ADP-ribosylation of Gi, a regulatory
protein of the adenylate cyclase complex. The details of this mechanism will be
further discussed in a later section.
1.3.5. Interaction of pertussis toxin with the cell membrane
The mechanism of B-oligomer binding to a receptor and entry of the S-l
subunit has not been demonstrated. The lymphocytosis activity of the toxin is thought
to be the result of the interaction of the B-oligomer with host-cell receptors (Nogimori
et al..1984a and b) but these receptors have not yet been identified.
The toxin has been shown to bind to the oligosaccharide regions of several
glycoproteins such as haptoglobulin and fetuin (Irons and MacLennan, 1979; Sekura
and Zhang, 1985). Armstrong et al-(19871 further investigated the interaction of
toxin with fetuin in order to characterise its binding to carbohydrate and to demonstrate
its lectin-like properties. They concluded that two sugars - Neu Ac and Glc NAc
were the most important residues in toxin binding to complex carbohydrates. It was
suggested that the toxin's interaction with fetuin, and possible specific membrane
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receptors, also depends upon the correct orientation of the sugar groups and not upon
electrostatic interactions with the negatively charged carbohydrate groups.
As described above the toxin binds to a 165kDa glycoprotein with a terminal
Neu Ac > Gal(34GlcNAc on CHO cells (Brennan et aL 19881. This further
demonstrates that the toxin preferentially interacts with N-linked oligosaccharides
(Irons and MacLennan, 1979; Sekura and Zhang, 1985).
The oligosaccharide binding site on the B-oligomer has been further narrowed
down to the S-3/S-4 dimer as this is the region shown to directly
interact with the 165kDa protein. Both of the dimers, however, are capable of
haemagglutinating erythrocytes and can bind to fetui n. This suggests that there are
multiple lectin-like binding sites, with different specifiries, on the B-oligomer.
This work indicates that glycoproteins may serve as receptors for pertussis
toxin on other cell types. Brennan etal. (19881 have suggested that as pertussis toxin
plays a role in the adherence of B. pertussis to host cells, similar glycoproteins to
those discussed above may serve as attachment sites for the bacteria.
1.3.6. The entry of toxin into the cell
It is essential for S-l to cross the cell membrane to gain access to adenylate
cyclase, which is located within the inner membrane. This penetration is likely to
involve hydrophobic interactions between the toxin and the hydrophobic regions of
membrane lipids (Montecucco et al.^ 19861. As the S-l subunit has been shown not to
interact with membrane lipids, the B-subunits must shield the active peptide from
membrane interaction.
Several possible mechanisms for active peptide entry have been suggested for
cholera toxin; methods which may perhaps also apply for pertussis toxin. Firstly, van
Heyningen and King (1975) suggested that there is no specific mechanism involved in
the internalisation process but that, at a high local concentration of toxin, a few
molecules of toxin must enter the cell by some random process. Gill (1976) suggested
that the B-subunits could form a pore within the membrane through which the active
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described above, that the subunits of the B-oligomer do not all penetrate detergent
micelles, demonstrating the impossibility of pore production. Another possible
mechanism for the entry of S-l is endocytosis, but there is no evidence for this as the
toxin has never been found within endosomes. The model of greatest interest at
present is that once the B-oligomer is bound to a specific membrane glycoprotein it
will become internalised along with this glycoprotein in membrane regeneration. This
would enable the toxin to cross the membrane and reach the cytosolic side. There is a
noticeable lag period between the binding of the toxin to the cell membrane and
expression of activity (Katada and Ui, 1980). This lag period could be attributed to
the time taken for internalisation of the toxin. With cholera toxin the lag is also at
least partly due to the time it takes for the active peptide to separate from the rest of the
toxin. This may also be the case for pertussis toxin but the overall mechanism of its
entry has still not been demonstrated.
1.3.7. ADP-ribosylation and activation of adenylate cyclase
In 1979 Katada and Ui demonstrated that pertussis toxin had a marked effect
upon the receptor-mediated production of cAMP. This was later shown to result from
the toxin-catalysed ADP-ribosylation of a 41kDa membrane-bound protein (Kadata
and Ui, 1982a). ADP-ribosylation involves the enzyme-catalysed breakdown of
NAD+ to ADP-ribose and nicotinamide with the subsequent covalent modification of a
membrane protein via the addition of ADP-ribose to a cysteine residue on this protein
(West et al. 1985).
ADP-ribosylation is discussed further in Chapter 4. This pertussis toxin
catalysed ADP-ribosylation is responsible for the reversal of receptor-mediated
inhibition of adenylate cyclase activity leading to an increase in cAMP concentration
within the cell. The mechanism for toxin catalysed ADP-ribosylation is shown in Fig.
1.7.
The main protein substrate for ADP-ribosylation is Gi. This protein is involved
in regulation of adenylate cyclase and is normally under the control of inhibitory
hormones. There are at least two G-proteins involved in the regulation of adenylate
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cyclase, namely Gi - the inhibitory regulatory GTP-binding protein and Gs - the
stimulatory regulatory GTP-binding protein, Gs being the substrate for cholera toxin.
These G-proteins act as intermediates in the hormonal regulation of secondary
messenger concentrations within the cell (Bokoch et al^ 1982; Neer and Clapham,
1988; Milligan, 1988). Rodbell and co-workers (1971) were the first group to
demonstrate the requirement for guanine nucleotides in the activity of certain hormones
in hepatocytes and following these initial observations many G-proteins have been
isolated, which, although each is unique, are very similar in both structure and
function.
Both Gi and Gs have three different subunits a, P, and y (Hildebrandt, 1984),
with an overall molecular mass of between 80-90kDa. The a-subunit binds guanine
(nu*)
nucleotides, Gi a having a molecular mass of 41kDa. Katada and Uiwere the first to
show that pertussis toxin catalysed the ADP-ribosylation of this protein within rat C6
glioma cells, when the cells are incubated with [a-32P] NAD+. The toxin catalysed
the transfer of radioactive ADP-ribose to this membrane protein.
The a-subunit of Gs has a molecular mass in the range of 42-45kDa. The
primary sequences of Gsa and Gia are highly conserved and this conservation is
carried through to the tertiary structure (Milligan, 1988). Manning and Gilman,
(1983) suggested that there was a single P-subunit type, but this was later disprove ■
by Sternweiss and Robinshaw (1984), who were the first group to show that there
were distinct p-subunits for each a-subunit. Molecular cloning techniques have
subsequently confirmed the presence of at least two distinct p-subunit genes
(Sugimoto et aL.1985: Fong et al. 1987). Very little is known about the y-subunit.
Immunological evidence (Hildebrandt et ah . 1985) suggests that there are a number of
different forms, each being a small polypeptide of about 8kDa. In every situation so

















ACTIVATION/DEACTIVATION PROCESS OF THE ADENYLATE
CYCLASE CATALYTIC UNIT.
ADAPTED FROM MILLIGAN (1988)
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of this Py-complex is probably to anchor the associated apy-complex in the cell
membrane and may also be involved in communication with the rest of the cyclase
complex (Sternweiss, 1986).
The activation of Gi or Gs is dependant upon both guanine nucleotides and
Mg2+ ions (Hildebrandt and Birnbaumer, 1983). This activation is brought about by
the dissociation of the a-subunit from the aPy-complex. This activation is shown in
Figure 1.8.
The aPy form of Gi is known as the resting state of this protein complex
(Milligan, 1988). The a-subunit becomes active when it is dissociated from the Py-
complex (Hildebrandt et al. 1983; Khan and Gilman, 1984) and bound GDP is
replaced with GTP. The release of GDP is the rate-limiting step in the activation
process (Gilman, 1987; Milligan, 1988). Once GTP is bound to the a-subunit, and in
the presence of Mg2+ ions, the a-subunit can then interact with adenylate cyclase and
alter the rate of synthesis of cAMP. There is a cyclical pattern of activation and
deactivation which is completed when bound GTP is hydrolysed to GDP by the
intrinsic GTPase activity of the a-subunit. This a-subunit-GDP form can then
reassociate with the Py-complex reverting Gi back to its resting state. The effect of
both pertussis and cholera toxins is to inhibit the GTPase of Gi and Gs respectively
maintaining the active conformation of both proteins (Cassel and Selinger, 1977) and
resulting in an unregulated increase in the production of cAMP.
1.3.8. Other protein substrates for pertussis toxin
Pertussis toxin catalyses the ADP-ribosylation of many other G-proteins. As
with Gi, these G-proteins also serve as transducers communicating between receptors
and effectors in mammalian cells. Again, as with the adenylate cyclase system, the
first step in this transduction process is the recognition of a specific receptor by some
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extracellular signal such as hormones, neurotransmitters and autocoids. The receptor
can then interact with the effectors of the system. These are generally other enzymes
controlling the production of secondary messenger substances such as cAMP,
diacylglycerol or inositol phosphates, or secondly controlling ion channels which
regulate ion concentration within the cell.
These cascade processes eventually lead to other cellular activities such as
muscle relaxation and contraction, dermotaxis, exocytosis and endocytosis, energy
metabolism, cell proliferation and cell differentiation (Ui, 1988). As pertussis toxin
prevents G-protein inhibition of several of these cascade processes it can have far-
reaching effects upon the physiological regulation of cell function.
After Gi, the next protein substrate found for pertussis toxin was transducin.
Transducin is also a GTP-binding regulatory protein. It is found in the retina and
regulates the activity of a cyclic GMP phosphodiesterase via light activated rhodopsin.
This protein is another a(3y heterotrimer and is structurally homologous to the
adenylate cyclase GTP-binding regulatory proteins. Transducin is also ADP-
ribosylated by cholera toxin but the sites of ADP-ribosylation by each toxin are distinct
(Manning gtal, 1984). The visual signaling converting the GTP-bound a-subunit
plus (3g-dimer form to the resting state is prevented by the pertussis toxin catalysed
covalent modification of the a-subunit. The a-subunit of transducin has a molecular
mass of 39kDa.
Katada and Ui (1983), further identified another two pertussis toxin GTP-
binding protein substrates from rat brain. These proteins are again a(3y heterotrimers
and are known as Go and Ga40py. The roles of either of these two proteins in the
central nervous system is unknown.
The phospholipase C enzyme is another protein under the control of GTP-
binding proteins (Ui et al. 1985: Rappuoli and Silvestri, 1987). These G-proteins are
known as Gp and have been identified as substrates for pertussis toxin catalysed ADP-
ribosylation (Muryama and Ui, 1985; Kurose and Ui, 1985). Phospholipase C is
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responsible for the production of two secondary messengers - inositol triphosphate
and diacylglycerol, within the cell. A summary of pertussis toxin catalysed ADP-
ribosylation is shown in Fig. 1.9.
Many of the clinical effects of B. pertussis infection can be attributed to ADP-
ribosylation of G-proteins. For example, when animals which have been pretreated
with pertussis toxin are challenged with histamine, the normal compensatory
physiological response does not occur (Ui, 1988). The pertussis toxin catalysed
ADP-ribosylation prevents the a-adrenergic (Ri) induced release of catecholamine and
the histamine induced vasodilation is eventually fatal. This effect is known as
histamine sensitisation, pertussis toxin also being known as histamine-sensitisation
factor (Okajuma and Ui, 1984; Okaiuma et al. 1985). The a-adrenergic blockage may
also be responsible for the toxin induced hypoglycaemia (Yaiima et al. 1981). As the
a-adrenergic system is responsible for inhibition of insulin secretion, once the system
becomes non-functional unregulated insulin secretion can result. This may explain the
islet-activating activity of the toxin (Katada and Ui, 1979), this activity again probably
resulting from the pertussis toxin catalysed ADP-ribosylation of Gi. Pertussis toxin
blockage of the a-adrenergic response therefore results in adrenal increasing insulin
production by a [3-adrenergic (Rs) mechanism.
Pertussis toxin can modify the growth of CHO cells causing the cells to cluster
and overlap in a similar way to transformed cells. This effect on CHO cells has been
related to ADP-ribosylation (Guerrant et aU 1974). The transformation process may
be interesting as the p21 ras oncogene products show similarities to G-proteins. The
p21 proteins are a group of highly related proteins which show amino acid homologies
with both transducin and the GTP-binding elongation factors (Lochrie et al.. 1985).
The p21 proteins are membrane bound and GTP-binding, but they have unknown
functions. It has been suggested that they may have similar functions to Gi and Gs.
ADP-ribosylation of the ras proteins could therefore result in some cellular enzymes
being permanently active leading to the uncontrolled cell-proliferation associated with
transformed cells. ADP-ribosylation of the p21 ras proteins has not been detected by
FIGURE 1.9
SUMMARY OF PERTUSSIS TOXIN CATALYSED
ADP-RIBOSYLATION.






either cholera (Gill and Wodkalis, 1985) or pertussis toxin (Ui, 1988). The yeast
Saccharomyces cerevisiae produces a ras protein which has a molecular mass greater
than p21 and has been shown to be a regulator of adenylate cyclase However, again
there is no evidence that this protein is ADP-ribosylated by pertussis toxin or any of
the other bacterial toxins.
Pertussis toxin can therefore be used as an effective biological tool to help in the
understanding of cellular communication with the toxin being used for the
identification of regulatory G-proteins.
Most of the effects of pertussis toxin, as discussed above, are due to ADP-
ribosylation but it is important to note that some of the activities such as lymphocytosis
and leukocytosis and adjuvancy effects forXgE are thought to depend only on binding
of toxin (Nogimori et ah. 1984a and b).
1.4. Other toxins
Many of the other bacterial protein toxins show similarities top^rtussis toxin in
three main ways. Firstly, in their two-component A-B structures, secondly, in their
mechanisms of action and finally in the way they bind to cells. Examples of other
toxins which exert their biological activities by ADP-ribosylation are cholera toxin^E.
coli heat labile toxin, diphtheria toxin and exotoxin A of Pseudomonas euruginosa.
Vaccines to the diseases associated with these toxins are made up of toxoids of these
ADP-ribosylating toxins, for example, cholera and diphtheria, and these vaccines have
been found to be practically, if not totally effective. Each of these toxins will be
discussed in the following section along with the neurotoxins of tetanus and
botulinum. A table showing the similarities of these toxins is shown in Table 1.4.
1.4.1. Cholera toxin
Infection of the human gastrointestinal tract by the bacterium Vibrio cholera
results in the disease cholera. The symptoms of this diseaseuve severe diarrhoea
resulting in extensive loss of fluid, which may be as much as twenty litres per day,
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causing severe dehydration and in some cases causing death only a few hours after the
onset of the disease symptoms. V. cholera, like B. pertussis, is a non-invasive
organism. The disease symptoms are attributed to cholera toxin, a potent exotoxin
produced by the bacteria. The way in which cholera toxin exerts its biological effects
is very complex but they all result from activation of the adenylate cyclase of intestinal
cells. This activation results in elevation of cellular cAMP levels and disruption of the
normal ion fluxes of the intestinal epithelium (Middlebrook and Dorland, 1984).
Cholera toxin activates adenylate cyclase via Gs, the stimulatory regulatory
protein of this complex. The toxin catalyses the ADP-ribosylation of this GTP-
binding protein maintaining it in its as-GTP bound active conformation, resulting in
the accumulation of cAMP within cells (Pfeuffer, 1977). The amino acid which is
modified by cholera toxin is arginine (Moss and Vaughn, 1977).
The toxin is composed of one A-subunit and five identical B-subunits. Each of
the B-subunits has a molecular mass of 11,600 and the A-subunit 27;000. The A-
subunit undergoes proteolytic cleavage upon activation producing an A1 peptide of 22,
000 and an A2 peptide of 5,000 molecular mass (van Heyningen, 1982). The B-
subunits bind to ganglioside GMI on the cell membrane (van Heyningen, 1977) and
this initial binding of the toxin must lead to the internalisation of the enzymically active
A-subunit within the cell. The mechanism of entry is still not fully understood. The
A2 chain is thought to be involved in the interaction of the A and B subunits,
facilitating the entry of the enzymically active A1 peptide into the cell (van Heyningen,
1982). The A1 peptide has been compared to S-5 of pertussis toxin, however, on
sequencing the genes no sequence homology was found (Nicosia et ah 1986).
1.4.2. E. coli heat-labile toxin
Certain strains of E. coli also secrete a toxin which activates adenylate cyclase.
This protein is known as heat-labile toxin (LT) and causes diahorrea in the same way
as cholera toxin. This toxin has the same subunit arrangement as cholera toxin
(Clements et al. 1980) with five B-subunits and one A-subunit which is made up of an
A1 and an A2 peptide, the Al peptide catalysing the ADP-ribosylation of an arginine
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residue on Gs (Gill et al. 1981; Moss and Vaughn, 1981). The DNA sequences of
both cholera toxin and heat-labile toxin shows a significant identity of 95% (Splicer et
al, 1981) and they are thought to be derived from the same ancestral gene. LT has also
been shown to bind to GM1 ganglioside (Parkinson and van Heyningen, 1989).
1.4.3. Diphtheria toxin
Diphtheria toxin is synthesised by Corneybacterium diphtherias and one
molecule of this toxin is sufficient to cause death of a single cell. The toxin is
synthesised as a single polypeptide chain which subsequently undergoes proteolytic
cleavage into an A-ffagment of 24 000 and a B-fragment of 38 000 molecular mass.
The two fragments are held together by a single disulphide bond.
The receptor for this toxin is thought to be a cell-surface glycoprotein and the
toxin binds to this receptor via the B-fragment, again resulting in the entry of the A-
fragment into the cell. Once the A-fragment has dissociated from the B it catalyses the
ADP-ribosylation of elongation factor 2 (EF-2). This ADP-ribosylation prevents
protein synthesis and leads to cell-death (Honjo et al.. 1968). The residue which is
modified by diphtheria toxin is diphthamide, a modified histidine residue which is
only found in EF-2 (van Ness etal., 1986).
1.4.5. Pseudomonas euruginosa exotoxin A
This toxin has the identical enzymic activity to diphtheria toxin. Both toxins
catalysing the NAD+-dependent ADP-ribosylation of elongation factor 2 (EF-2).
Exotoxin A is also synthesised as a single precursor chain which is processed into A
and B fragments. The mature fragments have molecular masses of 27 000 for A and
15 000 for B. As with the other toxins already discussed exotoxin A fragment B is
responsible for receptor binding and A fragment internalisation (Igleweski and Kabat,
1975; Igleweski et al.^ 19771. Although exotoxin A and diphtheria toxin have
structural similarities they do not cross-react immunologically and do not bind to the
same cell-surface receptor.
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The three-dimensional structure of exotoxin A has been resolved by X-ray
crystallographic techniques (Brandhuber et aL 1988). The structure solved is the
proenzymic form of the protein, ie. the form it takes before becoming internalised.
The group have proposed a model for the interaction of NAD+ with exotoxin A which
involves minor shifts, of less than one A, in the backbone and position of the side
chains upon binding of substrate. The nicotinamide ring of NAD+, appears to stack
on the whole ring of Trp 466, while the positively charged groups of Arg 456 and 467
form an ion bridge with the phosphates of NAD+. Tyr 481 has been shown to interact
with the purine ring of the adenine moiety of NAD+. Tyr 470 participates directly in
catalysis and is positioned near the nicotinamide-ribose bond which is broken down
during catalysis. This proposed model is further confirmed by site-directed
mutagenesis. Diphtheria toxin utilises similar catalytic residues and has a structurally
similar binding site to that of exotoxin A so the X-ray structure data for exotoxin A
may also apply to diphtheria toxin (Brandhuber et aD 19881.
1.4.5. The cytotoxins of Clostridium botulinium
Several of the clostridial bacteria produce toxins which ADP-ribosylate
monomelic actin. These include botulinium C2 toxin, Clostridium perfringens iota
toxin, Clostridium spiroforme toxin and a toxin produced by Clostridium difficile.
These toxins, by ADP-ribosylating monomelic G-actin, inhibit polymerisation of the
monomelic form by preventing further polymerisation at the end of actin filaments,
resulting in the breakdown of the cytoskeleton (Aktories and Wegner, 1989).
C2 toxin is another two-component toxin, with component II being responsible
for binding and component I being enzymically active. The mass of component II is
100 000 and of component I is 50 000. C2 toxin ADP-ribosylates non-muscle actin
on Arg 177 (Vanderkerchove et al. 1988). C. perfingens iota toxin modifies Arg 177
in skeletal muscle actin, so the specificity of ADP-ribosylation depends not only on the
type of actin isoform but also on the toxin.
It has recently been shown that certain strains of Clostridium botulinium type C
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produces a second ADP-ribosyltransferase, C3, which is distinct from toxin C2
(Aktories et al. 1987-). This toxin catalyses the ADP-ribosylation of a 21-24kDa GTP-
binding protein found in various cell types. It has also been reported that toxin CI and
D ADP-ribosylate a 21kDa GTP-binding protein which is involved in the inhibition of
exocytosis (Ohashi et al.. 1987) but Rosener et al.; (1987) have suggested that this
observation is only as a result of contamination of preparations of CI and D with toxin
C3. This latter suggestion is now believed to be correct.
1.4.6. The neurotoxins of Clostridium botulinium
Clostridium botulinium produces at least nine different toxins, types C2 and C3
being the cytotoxins discussed above and types A, B, CI, D, E, F and G being
neurotoxins. The neurotoxins block the release of neurotransmitters at cholinergic and
other synapses resulting in the flaccid paralysis which is characteristic of this disease
(Habermann and Dreyer, 1986). All seven toxins have a similar general structure
consisting of a heavy and light chain which are joined by a disulphide bond. The
heavy chain is responsible for binding to a cell-surface receptor, but neither chain has
been shown to be enzymically active.
1.4.7. Tetanus toxin
Tetanus toxin is a neurotoxin secreted by Clostridium tetani and is responsible
for the dramatic muscular spasms characteristic of the disease tetanus. Very little is
known about the cellular or molecular events which result in the manifestation of this
clinical disease. This is probably due to the site of action of this toxin being the
central nervous system, which is itself very complex and not fully understood.
The toxin binds to peripheral nerve terminals, where it is internalised and
transported by retrograde axon al transport to the cell body (Price et al. 1975). The
toxin migrates trans-synaptically until it reaches the inhibitory synpases of the spinal
cord or brain stem. The toxin causes its spastic paralysis by blocking the release of
neurotransmitters, especially gamma-aminobutyric acid (GABA), from these
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inhibitory synapses. This inhibition of neurotransmitter release leads to the
uninhibited firing of neurons and the characteristic spastic paralysis of tetanus.
The toxin itself is composed of a heavy chain of molecular mass 100 000 and a
light chain of 50 000 molecular mass. Like diphtheria toxin, tetanus toxin is
synthesised as a single polypeptide chain precursor, which is proteolytically nicked
into heavy and light chains which are both held together by disulphide bonds (Craven
and Dawson, 1973). Recent evidence has shown that the heavy chain is responsible
for binding to a specific cell-surface receptor and micro-injection of the light chain into
cells leads to inhibition of catecholamine release from adrenal chromaffin cells (Bittner






























































































































































































































INicotinamide-4-3H]NAD+, TRA.298 ; 925MBq (18.5-92.5GBq/mmol)
and [carbonyl-14C) NAD+, CAA 372, 370kBq (11 - 18.5GBq/mmol) were
purchased from Amersham International, plf Amersham, Buckinghamshire,
England.
[U-14C]cysteine and [adenine-2-8 3H]NAD+ were from Dupont (U.K.)
Ltd., Wedgewood Way, Stevenage, Hertfordshire, England.
"Optiphase Safe" scintillation fluid was from Pharmacia, LKB
Biotechnology, S-75182, Uppsala, Sweden.
Other materials and reagents
Adenosine 5'-diphosphoribose (ADP-ribose), Adenosine 5'-
monophosphate (AMP), Bovine serum albumin, 4-chloro-l-naphthol, L-cysteine
methyl ester (hydrochloride), dimethyl subermidate, l-ethyl-3-[dimethyl-amino
propyl] butyric acid N-hydrosuccinimide ester, snake venom phosphodiesterase
and ovalbumin were from Sigma Chemical Co., Poole, Dorset, England.
NAD+ (Grade 1, 100%) was from Boehringer Mannheim, (UK), Bell
Lane, Lewes, East Sussex, England.
Silver nitrate and other analytical reagents were from B.D.H. Chemicals,
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Poole, Dorset, England.
Ditbobis (succinimidyl propionate) (DSP) and disuccinimidyl tartarate
(DST) were from Pierce Chemical Co., P.O. Box 1512, 3260BA Oud-Beijerland,
The Netherlands.
Cyanogen bromide activated sepharose 4B was from Pharmacia LKB
Biotechnology, S-75182, Uppsala, Sweden.
Dowex AG-IX (200-400 mesh, chloride form) was purchased from Bio
Rad, Watford, Hertfordshire, England.
Spectrapor dialysis membrane was from Spectrum Medical Industries,
60916 Terminal Annex, Los Angeles, U.S.A.
[12-[(phenyl methyl) amino]dodecan<yl]guanidine (A599) and [10- (acetyl
amino) decanyl] guanidine (A603) were made available as intermediates from
synthetic programmes within the Glaxo Research Group Ltd. VaLjuva QolvJuyi
i IcvacUVX
, li K.
All other reagents were analytical grade.
2.2 METHODS
2.2.1 Preparation of pertussis toxin - general method
Pertussis toxin was purified from culture supernatants of Bordetella
pertussis. The method followed was that of Irons and MacLennan (1979) and
Sekura et al. (1983). The following flow diagram outlines the general method of
toxin purification.
Freeze-dried B. pertussis (Wellcome strain 28), 0.5ml, is




agar plates (oxoid CM119) containing 10% w/v defibrinated horse
blood.
v
Growth from these plates i 5 used to innoculate seed
cultures containing 100ml of CL+CD medium (discussed in
Chapter 3). Seed cultures are grown at 35°C for 24 hours.
V
9ml of seed culture is used to innoculate Thompson flasks
containing 300ml of medium. The cultures were grown for
48-58 hours when bacterial growth was at its maximum.
The O.D. of the culture must be >6 which corresponds
approximately to 2.5mg dry weight of bacteria per ml.
v
Cultures centrifuged for 75 mins at 5000rpm
Supernatant removed and filtered through 0.22(1 filter to
remove all contaminating cells.
v
Culture supernatant is then passed through a hydroxyl
apatite column. This column binds filamentous
haemagglutinin, the other major secreted protein of B.
pertussis and allows pertussis toxin to pass straight
through.
V
The eluate is precipitated with (NH^SC^ to a final concentration
of 74% saturation
Y
The ammonium sulphate precipitated protein is centrifuged at 4000
rpm for 1 hour, the supernatant removed and the pellet
resuspended in 0.05M phosphate, 50mM NaCl buffer, pH 7.2.
The suspension is centrifuged at 15000 rpm for 20 minutes,
supernatant decanted and the pellet extracted four times
with phos/NaCl buffer. The supernatants are combined and
dialysed overnight.
y




Pertussis toxin binds specifically to this column and is
eluted with 6.7mM tris, 0.13M NaCl, 3M MgCl, pH. 6.4
buffer.
40 x 50 drop fractions are collected and each fraction
measured for its haemagglutinin activity with goose
erythrocytes.
V
Those fractions with haemagglutinin titre >7 are pooled and
measured for protein content.
The purified pertussis toxin is run on an SDS polyacrylamide gel to confirm the
homogeneity of the preparation.
2.2.2. ELECTROPHORETIC TECHNIQUES
2.2.2.1 SDS polyacrylamide gel electrophoresis (P.A.G.E.)
general method
Polyacrylamide gel electrophoresis was routinely carried out under
denaturing conditions by the addition of 0.1% (w/v) SDS in both the separating and
stacking gels. The gel system was based upon that of Laemmli (1970) with the
addition of 2mM EDTA. to chelate metal ions which may interfere with the
polymerisation of acrylamide and cause aggregation of proteins (Douglas and
Butow, 1976). Protein samples were electrophoresed for 1 hour at 100 volts while
the proteins moved into the stacking gel and then at 75 volts overnight.
Gels were fixed in 20% (v/v) methanol, 10% (v/v) acetic acid for 15
minutes, stained in 0.25% (w/v) Coomassie brilliant blue R-250, 45% (v/v)
methanol, 9% (v/v) acetic acid for 15 minutes at 55°C and destained in methanol
5% (v/v), 7.5% (v/v) acetic acid at 55°C until the background was clear. The
addition of polystyrene quickened the destaining process by absorbing the dye.
For determination of molecular masses, gels were calibrated with the
following standard proteins: bovine milk a-lactalbumin (14.2kDa), soybean
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trypsin-inhibitor (20.1kDa), bovine pancreas trypsinogen (24kDa), bovine
erythrocyte carbonic anhydrase (29kDa), rabbit muscle gluuraldehyde-3-phosphate
dehydrogenase (36kDa), rabbit phosphorylase b (subunit) (97.4kDa), E. coli (3-
galactosidase (subunit) 116kDa and rabbit muscle myosin (subunit) 205kDa .
These proteins were supplied as kits from Sigma Chemical Co: Dalton Mark VII-
L™ molecular mass marker kit for determination of molecular masses in the range
14.2kDa to 66kDa and the higher molecular mass standard mixture for
determination of molecular masses in the range 29kDa up to 205kDa.
2.2.2.2. Gradient polyacrylamide gel electrophoresis
Gradient polyacrylamide gel electrophoresis was earned out essentially as
outlined above. 5 - 20% (w/v) acrylamide and 10 - 20% (w/v) acrylamide
gradient polyacrylamide gels were poured using a Biorad 305 model gradient
former. Protein samples were again electrophoresed at 100 volts, while the
proteins moved into the stacking gel and then at 75 volts overnight. The gels were
fixed, stained and destained as outlined above.
2.2.2.3. Western blotting
Proteins were separated by SDS PAGE and transferred onto nitrocellulose
essentially by the method of Towbin et 31.^(1979). Following transfer, unreacted
binding sites were blocked by a 2 hour incubation in 0.3% (v/v) Tween 20, 1%
(w/v) BSA in phosphate buffered saline pH. 7.2. The nitrocellulose was then
washed with 5ml 0.3% Tween 20 in PBS for 3 x 5 minutes. The nitrocellulose was
next incubated for two hours with a solution of first antibody, consisting of a 1:50
dilution of ascites fluid containing polyclonal antibody directed against one of the
pertussis toxin subunits. The strips were again washed in 5ml of PBS/Tween 20
for 3 x 5 minutes after which time second antibody, the anti-mouse, horse-raddish
peroxidase conjugate, was added and the strips incubated for a further 2 hours.
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The strips were washed for a final 3x5 minutes in PBS and the bands were
visualised with 4-chloro-l-naphthol (0.02% w/v) dissolved in 1ml of methanol and
made up to 50ml with PBS. This was added to the washed strips with lOpil of
H202. The bands generally took 5-10 minutes to develop and the reaction was
stopped by immersing the strips in H20.
2.2.2.4. Silver staining.
The method used was essentially that of (Wary et al. 1981).
0.8g of silver nitrate was dissolved in 4ml of H20 and added dropwise, on
stirring, to 21 ml of 0.36% (w/v) NaOH and 1.4ml of concentrated NH3 solution.
This solution was made up to 100ml with H20. The SDS polyacrylamide gel
which had been soaked overnight in 50% MeOH was soaked in this solution for 15
minutes. After the soaking period the gel was washed for 3 x 5 minutes with
distilled H20 and developed in 500ml of 0.5% (v/v) formaldehyde, 1% (v/v)
acetic acid solution. The gel was generally developed in 5 minutes and
development was stopped in 25% (v/v) isopropanol, 10% (v/v) acetic acid solution.
2.2.2.5. FPLC separation of pertussis toxin subunits
2ml of 3-4mg/ml ammonium sulphate suspension of pertussis toxin was
pelleted at 13000 rpm in an MSE microcentaur and the protein resuspended in 10ml
of 6M guanidinium chloride in 50mM sodium phosphate buffer, pH. 6.5 and
stored at room temperature overnight. The sample was then extensively dialysed
against 500ml of 8M urea in phosphate buffer for two days with frequent buffer
changes to ensure the removal of the guanidinium chloride. The sample was
applied to a Superose 12 FPLC column which had been pre-equilibrated in 50mM
sodium phosphate, 0.5M NaCl, 8M urea pH 7.0 buffer. The column was eluted
with the same buffer at a flow rate of 0.2ml/min. 50 x 1 ml fractions were collected
and those fractions containing protein, as shown by their absorbance at 280nm,
were alysed by SDS PAGE.
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2.2.3. NAD+STUDIES
Assay of NAD+-glycohydrolase - general method
The NAD+-glycohydrolase activity of pertussis toxin was estimated
indirectly by measuring the rate of [3H]-nicotinamide release from [4-3H] NAD+ by
the method of Moss and Vaughn (1984). The ass^contained 20mM potassium
phosphate, pH. 6.5, 250mM dithiothreitol, lmg/ml ovalbumin, concentrations of
NAD+ ranging from l|iM - 200|iM containing 20|iCi [4-3H] NAD+ and 10|ig of
pre-activated toxin, in a total volume of 300|ll. The assays were initiated by the
addition of pre-activated pertussis toxin to the remaining constituents and incubated
for 4 hours at 30°C. 0.1 ml of products were applied to columns (0.5 x 2cm) of
Dowex AG-IX resin (200 - 400 mesh, chloride form, supplied by Bio Rad)
The columns were previously washed twice with 1ml of H20. [3H] nicotinamide
was eluted with five 1ml portions of 20mM tris , pH. 7.5 buffer and 1 ml sample
of the eluate added to 5ml of scintillation fluid and counted for radioactivity. The
pmoles of nicotinamide produced per hour can then calculated.
2.2.3.2. Activation of pertussis toxin
Pertussis toxin was activated prior to its use in the NAD+-glycohydrolase
assay by reduction of„disulphide bond in the S-l subunit. The activation buffer
consisted of 200mM potassium phosphate pH. 6.5; 20mM dithothreitol and 1%
(w/v) BSA. Toxin was activated in this buffer for 30 minutes at 30°C.
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2.2.3.3. Determination of the efficiency of NAD+-
glycohydrolase
The efficiency of the Dowex AG-1X2 separation of NAD+ and
nicotinamide was demonstrated by paper chromatographic separation of the NAD+-
glycohydrolase reaction products and comparing this separation with the resolution
of [4 3H] NAD+ and [3H] nicotinamide standard solutions. A mixture of ljlCi [4
3H] NAD+: l|lCi [3H] nicotinamide was made up in 200mM phosphate buffer, pH.
6.5 to a total volume of 300|il. 100|il of this mixture was added to two columns,
the remaining lOOp.1 being used as a control. The columns were washed with 5ml
of 20mM Tris, the control sample being diluted to a final volume of 5ml, and 20pl
of each applied to a strip of Whatman 3mm chromatography paper.. The reaction
products were separated in a mobile phase of isobutyric acid: NH4OH: H20 in the
ratio 66:1:33 for 4 hours. The strips were then dried and cut into 1cm x 2cm
portions and placed in scintilation vials containing 1ml of H20 and washed for 30
minutes. The strips were then removed and 10ml of scintillation fluid added to the
vials. Each sample was counted for 3H activity.
2.2.3.4. Sulphydryl reagents as potential substrates
The requirment for such a large dithothreitol concentration within the
NAD+-glycohydrolase assay mixture was investigated by essentially the same
method as outlined in section 2.2.3.1. The rate of [3H] nicotinamide release from
[4 3H] NAD+ was again determined, only in this case at saturating levels of NAD+
(100(lM) and with dithiothreitol concentrations ranging from 50mM - 1M. The
remaining assay constituents were as before. The pmoles of nicotinamide released
per hour were again calculated. This procedure was repeated using the sulphydryl
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reagent cysteine, p-mercaptoethanol and glutathione.
2.2.3.5. HPLC separation of NAD+-glycohydrolase reaction
products
The products of the NAD+-glycohydrolase reaction, as outlined in section
2.2.3.1., were separated by HPLC. The reaction products were firstly filtered
through an Amicon OM-IO filter, to remove all protein, and then the sample applied
to a reverse-phase ODS HYP 2734 column, dimensions 25cm x 4.6cm. The
mobile phase was 90% (v/v) lOmM ammonium dihydrogen phosphate, pH. 3.5
10% (v/v) methanol run at a flow rate of lml/min. The chart recorder was set at
lcm/min. The absorbance of the eluate was measured at 254nm using Altex
equipment.
The system was characterised using ADP-ribose, NAD+, AMP and
nicotinamide as standards enabling most of the reaction products to be identified.
2.2.3.6. Identification of reaction products using
radioactive compounds
Products of the NAD+-glycohydrolase reaction were separated by reverse-
phase HPLC as previously described, only in this case the assay mixture contained
[adenine-2-8 3H] NAD+ (2.5pCi/p.mol) and [U14C] cysteine (1.3|lCi/mmol). The
eluate was collected as 90 x 5 drop fractions directly into scintillation vials and each
fraction counted for both [3H] and [14C] radioactivities. The peaks of radioactivity
were matched with their corresponding peaks on the HPLC trace. In the case of
cysteine, which does not absorb at 254nm, a standard solution of [U-14C] cysteine
was applied to the column and 90 x 5 drop fractions collected, each fraction being
counted for 14C radioactivity,
be plotted on the trace.
48
From this run the elution position of cysteine could
2.2.3.7. Isolation of putative ADP-ribosyl-cysteine
From the elution time of this reaction product, the fractions containing this
compound were collected and concentrated by ffeeze-drying. The isolated product
was run on the HPLC at high sensitivity to demonstrate the homogeneity of the
preparations.
2.2.3.8. Reaction of snake-venom phosphodiesterase
The isolated reaction product was incubated with snake-venom
phosphodiesterase for 5 hours at 37°C. The products of this reaction were filtered
through an Amicon OM-IO filter to remove all protein and the sample applied to the
HPLC column to identify the reaction products.
2.2.3.9. Equilibrium dialysis
These studies were carried out in Teflon cells (Dianorm "R", Fisons Ltd).
Each of the cell consists of two teflon half-cells of total volume 250pl which are
separated by a dialysis membrane (Spectrapor) of molecular weight cut-off 6 000 -
8 000. Five such cells are arranged in an assembly which is gently rotated in a
waterbath at constant temperature. The buffer used for binding experiments was
0.1M sodium chloride, lOmM potassium phosphate, pH. 7.5, 1M urea. Buffer
containing [4-3H] NAD+ (20|iCi) and concentrations of unlabelled NAD+ from
l|iM up to 200|iM in a total volume of 200|il was injected into one half-cell.
Pertussis toxin at concentrations of 1.4-1.7 mg/ml, depending upon experiment,
was also added to this buffer in a total volume of 200JJ.1 and injected into the other
half-cell.
49
Several preliminary experiments were carried out in order to characterise the
system. The time taken to reach equilibrium was determined in a toxin-free system
and shown to be 3 hours. The non-specific breakdown of NAD+ to ADP-ribose
and nicotinamide during the dialysis procedure was found to be negligible and
finally the overall recovery of radioactivity was shown to be >95% in all cases.
2.2.3.10. Fluorescence measurements
Fluorescence titrations were carried out in a Perkin-Elmer MPF-3000
spectrofluorimeter containing a thermostatically controlled cuvette holder. The
excitation and emission slits were set at 15nm and 5nm respectively. Titrations
IOr*M
were performed by adding 5-10|ll increments of NAD+ inApostassium phosphate
, 0.1M sodium chloride, pH. 7.5 buffer to a 2ml solution of O.lmg/ml
pertussis toxin in the same buffer. The samples were carefully stirred after each
addition, ensuring that light was always excluded from the system. The decline in
protein fluorescence was measured at 340nm emission, 280nm excitation. The
temperature of the samples was kept constant at 23°C, 30°C or 40°C. In order to
correct for inner filter effects a solution of pertussis toxin, at the same concentration
as used for fluorescence titrations, was similarly titrated in a Perkin-Elmer
spectrometer at 280nm and corrections were made according to Honore and
Pederson (1989). All data m.(t corrected for dilution.
2.2.3.11. Circular dichoism of pertussis toxin
To ensure that 1M urea had no effect upon the tertiary structure of pertussis
Uoril
toxin, and thus^have no effect upon the binding of NAD+, circular dichroism
spectra were obtained in the presence and absence of urea. This work was carried
out at CAMR, Porton Down. The appropriate buffer blanks were subtracted in
each case and scans were carried out in the near U.V. (300 - 250nm) and in the far
50
Mota/ ,
U.V. (250 - 200 nra). All spectra expressed as mean residue eflipticity [p] as
degree cm2/dmol against wavelength (nm).
MRW x _©_ ,
100 LC
measured elipticity
cell pathlength in dm
concentration in g/ml (measured by micro-Kjeldahl)(l\iqai)0A am
mean residue weight = OIgIqcmIcw atos j loluA ivuvwW c j awiwo cm
for pertussis MRW - hq
Cross-linking studies
Cross-linking of pertussis toxin subunits
An ammonium sulphate suspension of pertussis toxin containing 5mg of
pertussis toxin was pelleted by centrifugation at 13 000 rpm in an MSE
microcentaur and resuspended in 5ml of 0.1M potassium phosphate, 0.5M NaCl
pH. 7.5 buffer and dialysed against this buffer to remove all contaminating
ammonium sulphate. Cross-linking reagents were dissolved in DMSO and added
to aliquots of the lmg/ml toxin solution to a final concentration of ImM or lOmM.
The reaction mixture was left at room temperature for 4 hours with constant mixing
after which time SDS was added to a final concentration of 1% (w/v) and the
samples boiled for 5 minutes. After boiling, the samples were applied to a 5% -
20% (w/v) or 10% - 20% (w/v) gradient acrylamide SDS polyacrylamide gel.
2.2.4.2. Two-dimensional SDS-polyacrylamide gel
electrophoresis
Cross-linked pertussis toxin subunits were separated on a lst-dimension









gradients of 5-20% (w/v) acrylamide or 10-20% (w/v) acrylamide. Strips were cut
from these gels and treated in one of the following ways.
1. The excised strip was soaked in a solution of 0.1M tris, lOmM
dithiothreitol pH. 6.8 buffer for 2 hours. The strip was then
attached to the top of a second dimension 17.5% polyacrylamide gel with
agarose and the proteins run into the separating gel as before.
2. The excised strip was attached to a 17.5% separating gel with agarose
and the cross-linked subunits allowed to penetrate the separating
gel which contained lOmM dithiothreitol. Once the cross-linked
subunits had penetrated this gel, the current was switched off for 2
hours, after which time the current was reapplied and the gel run to
completion.
3. The final methodvitoa modification of (2) in which lOmM
dithiothreitolvte only incorporated within the stacking gel. The
cross-linked subunits from the 1st dimension are allowed to
penetrate the stacking gel, the current then being turned off for 2
hours, reapplied, and the gel run to completion.
2.2.4.3. Electroelution
Strips of polyacrylamide gel containing protein were removed from the gel
and cut into 10 Wtdn 10* ZtwfThese were positioned in the large cup of the
Iatti electroelution apparatus. The buffer used was lOmM potassium phosphate
pH 7.5, 1M urea. Application of current results in proteins migrating from the gel
matrix to the concentrating cup which holds a total volume of 50p.l.
tatc. Ivx. . J .IvvACCiVvN^ UOoJ. 06^,
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2.2.5. Determination of protein
Unless otherwise stated, protein was measured using the technique of
Lowry, et al . (1951). At CAMR the method used is an automated Lowry which is
calibrated with bovine serum albumin.
2.2.6. Liquid scintillation counting
All radioactive samples were counted in "Optiphase Safe" emulsifying
scintillant from LKB. For each experiment all samples were identical in volume of
scintillant and volume of sample. Background and standard vials were also counted
for each experiment. The background vials were identical in both sample volume
and volume of scintillant as the sample vials, except that they contained no
radioactive material. The standard vials contained a known amount of sample
containing a defined amount of radioactivity.
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CHAPTER 3
GROWTH OF BORDETELLA PERTUSSIS AND
PURIFICATION OF PERTUSSIS TOXIN
3.1. INTRODUCTION
3.1.1. Expression of pertussis toxin
Pertussis toxin is found in both the supernatant hntlcell pellets of B. pertussis
(Morse and Bray, 1969, Sato, et al.. 1974). Ashworth, et al.. (1985) showed, by
electron microscopy using a gold-labelled monoclonal antibody, that the toxin was
distributed all over the cell surface. Little is known on how the toxin is released into
culture supernatants. Evidence suggests that this secretion mechanism does not involve
the autolysis of cells (Sato, et al.. 1974; Perera, etal.. 1986) as it has been shown that
malate dehydrogenase, a cytoplasmic marker, does not appear in culture supernatants.
Locht and Keith, (1986) and Nicosia et al.. (1986) have both shown that each of the
pertussis toxin subunits contains a region at its amino terminal which is typical of a
bacterial signal peptide. This suggests that each of the subunits are synthesised
individually as precursor proteins whereupon they are secreted into the periplasmic
space, their signal peptides are subsequently cleaved and the mature subunits assembled
into the holotoxin molecule.
3.1.2. Growth of Bordetella pertussis
Maximum concentration of pertussis toxin is found at the end of the exponential
growth phase and the beginning of the stationary phase (Sato, et al.. 1974; Sekura, et
a!., 1983; Bellalou and Relyveld, 1984). A batch culture process is used in the
purification of pertussis toxin as Gorringe, (1988) showed that a greater amount of
pertussis toxin was obtained from batch culture (Stanier and Scholte, 1971), when
compared to continuous culture (Robinson, et al.. 1983). This is easily explained as
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continuous culture steady-state conditions are maintained in the mid-exponential phase
where production of pertussis toxin is not maximum.
3.1.3 Growth of Bordetella pertussis
3.1.3.1. Intiation of Growth
This work was kindly carried out by Dr. Andrew Gorringe, Vaccine Research
and Production Laboratory, P.H.L.S. Centre for Applied Microbiology and Research,
Porton Down.
Growth of B. pertussis strain Wellcome 28u)06initiated by resuspending 0.5ml of
the bacteria, which are freeze-dried in medium, and growing the resuspended cultures
on charcoal agar plates (oxoid CM 119) which contain defibrinated horse blood (10%
v/v). The resuspended bacteriaWW spread onto the surface of two charcoal agar plates
and the cultures grown at 35°C for 48 hours, after which time the growth from the
plateswdiCaused to innoculate seed cultures. These seed cultures are grown in 100ml of
CL + CD medium for 24 hours at 35°. After this incubation period 9ml of seed culture
UAs used to innoculate thirty 2.5 litre Thompson flasks (2 5cm x 15cm x 7-5 cm).
3.1.3.2. Growth medium
The strain of Bordetella pertussis used for purification of pertussis toxin is strain
Wellcome 28. The cultures are grown in Thompson bottles, each containing 300ml of
medium, and incubated at 35°C on a shaker. 2,6-0 dimethyl (3-cyclodextrin (MeCD) is
added to the medium as it has been shown to stimulate production of pertussis toxin by
about two-fold (Imaizumi, et al„ 1983a and b). It is added to CL+CD medium to a
final concentration of lg/t
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3.1.3.3. Preparation of CL and CD medium
The additions for CL + CD medium are prepared as follows:
(a) 5g L-cysteine in 400ml 2.5M HC1
(b) l.Og FeS04-7H20 in 400ml of distilled H20
(c) 0.4g nicotinic acid in 400ml of distilled H20
The bottle for medium preparation is filled with 10 litres of distilled water and the














80ml of the cysteine/FeS04-7H20/nicotinic acid solution is then added to the 10
litres of medium and the total volume of medium is made up to 20 litres with distilled
water. The pH of the medium is then adjusted to 7.6 with HC1. 300ml of medium is
added to each Thompson bottle, with 30 Thompsons generally being used in one toxin
purification process.
The Thompson bottles are incubated at 35 °C for 24 hours before innoculation,
during which time any of the bottles which show signs of bacterial growth are
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discarded. 9ml of seed culture are then used to innoculate each of the Thompson fasks
and these are again incubated at 35 °C with shaking. Growth in the Thomspon flasks is
usually complete within 48-58 hours. This is confirmed by determination of the optical
density of the bacterial cultures at 550nm. When the O.D. 550nm is greater than 6 then
growth is complete as this optical density corresponds to approximately 2.5mg dry
weight of bacteria per millilitre of culture.
3.2. Purification of pertussis toxin
3.2.1 Introduction
Some of the properties of pertussis toxin complicate its purification process.
These are: firstly its increased insolubility in low ionic strength buffers as the
purification process proceeds, secondly that the toxin is inactivated by organic solvents
and by exposure to pH less than 3 and greater than 9, and finally that it is strongly
adsorbed to many of the routinely used chromatographic media.
Sato and Arai, (1972) and Sato, et al.. (1974) where first to purify pertussis
toxin. They used three consecutive steps of ammonium sulphate precipitation, followed
by starch-block electrophoresis and finally sucrose density gradient. However, this
method of toxin purification did not separate the two major haemagglutinins secreted by
the bacteria, namely pertussis toxin and filamentous haemagglutinin. Yajima, et al.,
(1978a) purified the toxin to homogeneity by firstly passing the culture supernatant
down a hydroxyl apatite column, then a Concanavalin-A-Sepharose column and finally
a Biogel P-100 column. They called their purified protein islet-activating protein as it
was shown to enhance insulin secretion for the p-cells of the pancreas. Their purified
toxin was also shown to have lymphocytosis promoting and histamine-sensitising
activities in mice (Yajima, etah, 1978b).
In 1979 Irons and MacLennan showed that pertussis toxin could be purified by
a one-step affinity chromatographic process. This was based on the observation that
pertussis toxin specifically bound to serum sialoglycoproteins. The affinity matrix used
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was human haptoglobulin coupled to Sepharose 4B. Pertussis toxin specifically bound
to this matrix and was eluted by a step-wise pH gradient. This method was then
modified by Sekura et al.. (1983) who coupled fetuin to Sepharose 4B as it was a more
commercially available glycoprotein. Sato, et al.. (1983) carried out a two-step
chromatography purification process firstly involving hydroxylapatite chromatography
and secondly haptoglobulin-Sepharose chromatography. This method enabled a good
separation of pertussis toxin from filamentous haemagglutinin at the hydroxylapatite
stage leading to a very pure toxin preparation. This affinity chromatography method is
the method routinely carried out at CAMR.
3.2.2 PURIFICATION OF PERTUSSIS TOXIN
3.2.2.1 Hydroxyl apatite chromatography
Once the O.D. of the bacterial culture has reached its maximum the 30 litres of
culture centrifuged at 5 000 rpm for 75 minutes whereupon the culture supernatant w&s
removed. The supernatantWothen filtered through a 0.22(i filter to remove all
contaminating cells. At this stage of the purification process the supernatant is mainly
composed of pertussis toxin and filamentous haemagglutinin. The filtered supernatant
vfav5then pumped through a hydroxyl apatite column.
The spherical hydroxyl apatite used was supplied by BDH Chemicals Ltd. 400g
of this powder was suspended in 500ml of 0.1 M NaCl and the mixture allowed to settle
at room temperature. The above procedure was repeated a further twice after which the
hydroxyl apatite is washed with several washes of distilled water until the pH of the
decanted solution is 8. The powderviwtfhen resuspended in lOmM K2HP04/KH2P04
buffer, p.H. 8, decanted and washed with a further three volumes of this buffer. The
hydroxyl apatiteutosuspended in this buffer and poured into the column. The column ooco
further washed with phosphate buffer for 7 hours at a flow rate of 400 ml/hr and
overnight at 200 ml/hr. This extensive washing is required to ensure that the final
bicarbonate concentration is less than 0.2%. The columnvioC)lW,r\ready for use.
The columnuto connected to a reservoir containing the concentrated filtered
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culture supernatants and the solution is pumped through the column at a flow rate of
200 ml/hr. The eluate is collected from the column and contains pertussis toxin,
filamentous haemagglutinin remaining bound to the column. Ammonium sulphate
(Aristar grade) is added to the eluate to a final concentration of 74% (50g of [NH4]2
S04 per 100 ml of eluate) and this is left overnight to precipitate pertussis toxin. The
precipitated eluate is then centrifuged at 4000 rpm for 60 minutes at 4°C. The pellet is
resuspended in 0.05 M phosphate, 0.5 M NaCl buffer, pH. 7.2 and this suspension is
further centrifuged at 15 000 rpm for 20 minutes. The supernatant is decanted and the
pellet extracted four times with the phos/NaCl buffer. A hand homogeniser is used each
time to resuspend the pellet and ensure a homogenous suspension. The supernatants
are combined and dialysed overnight against phos/NaCl buffer at 4°C. The dialysed
sample is then applied to a fetuin-Sepharose affinity column which has been pre-
equilibrated with the dialysis buffer.
3.2.2.2. Preparation of fetuin-Sepharose 4B
15 g of CNBr-activated Sepharose 4B is suspended in 100 ml of 1M HC1 and
applied to a scintered glass funnel (coarse grade 1 or 2) and washed with 2 litres of 1 M
HC1. 200mg of fetuin is then dissolved in 10 ml of 0.1 M NaHC03, 0.5 M NaCl, pH
8.1 buffer and dialysed against this buffer for 16 hours at room temperature. The fetuin
solution is next added to the washed Sepharose with 10 ml of 0.1 M NaHC03, 0.5 M
NaCl, pH 8.1 buffer. This suspension is then rotated end over end for 4 hours at room
temperature (the use of a magnetic stirrer was not advisable as it breaks up the
Sepharose beads). The suspension is then filtered, the filtrate being collected for Lowry
protein determination. The protein content of the filtrate should be low (<50jag/ml)
showing that most of the fetuin has bound to the Sepharose. The Sepharose is then
washed with a further 50 ml of NaHC03/NaCl buffer. This suspension is filtered and
the Sepharose resuspended in 100 ml of 1 M ethanolamine, 0.1 M borate, 0.5 M NaCl,
p.H. 9.0 buffer and left to equilibrate at room temperature for 2 hours. This suspension
is again filtered and washed with four alternate washes of 0.1 M borate, 0.5 M NaCl,
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p.H. 8.1 buffer and 0.1 M acetate, 0.5 M NaCl buffer, p.H. 3.8. The Sepharose is
now ready for use.
3.2.2.3. Fetuin-Sepharose 4B affinity chromatography
The dialysed sample is applied to the fetuin-Sepharose column which has been
pre-equilibrated with the dialysis buffer. The protein solution is loaded onto the
columns at a flow rate of 0.5ml/min and the eluate collected. The column is then eluted
with 50 ml of phosphate/NaCl buffer to wash off non-specific adsorbed components.
The column is further eluted with this buffer collecting 10 x 50 drop fractions (3 ml).
The column is then eluted with 6.7 mM tris, 0.13 M NaCl, 3 M MgCl p.H. 6.4 buffer
at a flow rate of 0.5 ml/min. 40 x 50 drop fractions were collected and those containing
pertussis toxin were determined via their haemagglutinin titre with goose erythrocytes.
3.3. RESULTS
3.3.1. Growth of Bordetella pertussis
Two consecutive cultures of B. pertussis were grown for the preparation of
pertussis toxin as outlined in 3.1.2. After 48 hours of growth in Thompson flasks the
optical density and p.H. of selected cultures were measured and the results for both
preparations - ML-1 and ML-2 are shown in Table 3.1. The cultures were ready for
centrifugation as the desired optical density was greater than 8 and the p.H. of the media
8.4.
The culture supernatant is prepared for fetuin-Sepharose 4B chromatography by
the consecutive steps of filtration, hydroxylapatite chromatography and ammonium
sulphate precipitation as shown previously. 40|"r0chon& QUiVxOO d'Offtwere collected and
tested for their haemagglutinin titre.
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3.3.2. HAEMAGGLUTININ TEST
3.3.2.1. Preparation of goose red blood cells
20 ml of fresh goose blood was added to a glass centrifuge tube, which was
filled to three quarters full with PBS. This suspension was centrifuged at 1^500 rpm for
5 minutes, the supernatant removed, and the pellet of red blood cells resuspended in
PBS. This process was repeated for a further two washes. After the final wash, 0.5 ml
of the packed red blood cells were resuspended in 100 ml of PBS. to a final
concentration of 0.5% (v/v) of washed goose red blood cells.
TABLE 3.1 Optical Density and p.H. of Selected B.
pertussis cultures.
Sample Optical Density p.H
ML-1 Sample 1 0.818 8.69
ML-1 Sample 2 0.862 8.50
ML-1 Sample 3 0.772 8.21
ML-2 Sample 1 8.08 8.32
ML-2 Sample 2 8.33 8.27
ML-2 Sample 3 7.97 8.33
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3.3.2.2. Haemagglutinin test
50[il of PBSuutadded to each well of a microtitre tray using an eight channel
automatic pipette. 50|il of each sample from the fetuin-Sepharose column wcothen added
to duplicate wells on the tray and diluted through the row, leaving two rows of wells
with no sample for control purposes. 50|il of freshly washed 0.5% (v/v) goose red-
blood cellsusethen added to each well and the blood cells allowed to settle until "clear
buttons" of red blood cells have formed in the control wells. The number of doubling
dilutions of each fraction where therew%no button formation in the wellwwthen counted -
the "haemagglutination titre" of each fraction. The titre of each fractionwcorecorded and
those fractions of titre greater than 7 are pooled and assayed for protein content by the
method of Lowry etal^l951). The results for preparations ML-1 and ML-2 are shown
in Table 3.2. The average protein content of preparation ML-1 is 0.6 mg/ml and of
preparation ML-2, 0.8 mg/ml. Both samples were run on an SDS polyacrylamide gel,
the gel is shown in Figure 3.1. The gel shows that all of the toxin subunits are intact.
The toxinwas stored as an ammonium sulphate suspension. The final protein
concentrations of the preparations after ammonium sulphate precipitation are ML-1, 3.2
mg of toxin per ml of solution and ML-2, 3.5 mg of protein per ml as measured by the
method of Lowry etal (1951).
FIGURE 3.1
17.5% (w/v) acrylamide SDS polyacrylamide gel of pertussis toxin
showing that all five subunits are intact in both ML-1 and ML-2
preparations.
Lane 1 50|il of ML-1 preparation
Lane 2 30pl of ML-1 preparation
Lane 3 lO^Ll of ML-1 preparation
Lane 4 10^1 of ML-2 preparation
Lane 5 30|il of ML-2 preparation





TABLE 3.2 Protein Content of Pertussis Toxin Preparations
ML-1 and ML-2 as Measured by the Method of
Lowry et al,(1951L









3.4. Isolation of pertussis toxin subunits
Pertussis toxin ammonium sulphate suspension was pelleted at 13 000 rpm and
resuspended in 6 M guanidinium chloride, 50 mM phosphate, p.H. 6.5 buffer. This
solution was t>Wv».d ovLwwM room This buffer - guanidinium
chloride solution was then dralysed extensively against 8 M urea with continual buffer
changes to ensure that all the guanidinium chloride was removed from the sample. In 8
M urea (Rappuoli and Silvestri, 1987) pertussis toxin subunits should be dissociated
into monomers of S-l, S-2, S-3, S-4 and S-5 and thus should be resolved using gel
filtration FPLC.
The Superose 12 column was pre-equilibriated with 8 M urea, 50 mM
potassium phosphate p.H. 6.5 buffer with five column volumes and then set at a flow
rate of 0.5 ml per minute, the flow rate being kept low as the buffer is viscous and the
pressure of the system must be kept below 3MPa. The toxin sample was filtered
FIGURE 3.2
FPLC SEPARATION OF PERTUSSIS TOXIN SUBUNITS.
ON THE BASIS OF MOLECULAR MASS:
1 - S-4/S-2 DIMER





through a 0.22(1 filter and applied to the column. 1 ml samples were collected from the
column. The trace of protein separation is shown if Figure 3.2 and those samples
... . . C.Uc.Wo
which contain protein, as indicated by their absorbance as 280nm, were Ion a 17.5%
S.D.S. polyacrylamide gel. The gel obtained demonstrated that the amount of protein
Otv\d so i
isolated was so small^preventszck the accurate determination of which subunits were
in each fraction.
3.5. DISCUSSION
In this chapter the techniques involved in the production and purification of
pertussis toxin were carried out. Two toxin preparations, ML-1 and ML-2 were
purified to homogeneity and an attempt at the FPLC separation of pertussis toxin
subunits was undertaken.
3.5.1. Purification of pertussis toxin
The toxin was purified to homogeneity by the methods of Irons and MacLennan
(1979) and of Sekura et al ("19831. About 30-50 mg of toxin are generally purified from
9 litres of culture supernate by the above procedure. The purified toxin was
055(t55cc| by protein content, SDS polyacrylamide gel electrophoresis and
haemagglutination titre. Several other in vivo assays were also carried out on the
purified toxin. These assays are only carried out on the final purified protein as they are
very expensive and subject to inaccuracy making in vitro assays more sensible for the
monitoring of fractions obtained during the toxin purification procedure. These in
vitro assays include analysis of the NAD+-glycohydrolase activity (Moss and Vaughn,
1984; Ribeiro-Neto^ et al 1985); Chinese hamster ovary cell assay (Hewlett etal,. 1983;
Gillenius et al. 1985) which involves the calculation of the minimum concentration of
toxin required to obtain complete cell clumping and enzyme-linked immunosorbent
assays (ELISA) Voller et al.,1980; Sato et ah. 1983).
Toxin preparations must be very stringently tested and characterised before use
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in subsequent experiments.
The toxin is stored in 50 mM tris, 0.5 M NaCl p.H. 8 buffer as a suspension in
saturated ammonium sulphate. The purity of the final toxin preparation is not less than
98% which contains 0.5-1% lipopolysaccharide endotoxin (LPS). Pertussis toxin
purified by the above procedures, as ML-1 and ML-2 is used in the production of the
CAMR acellular vaccine so the purity and activity of each individual preparation must be
determined to great accuracy.
3.5.2. Isolation of subunits
There is much controversy concerning the conditions required for the separation
of pertussis toxin subunits. Tamura etaL f 19821 reported that the toxin dissociated into
its subunits in urea concentrations greater than 2 M and that the subunits can be
separated on CM-Sepharose after further exposure to 5 M urea. This separation
resolved S-l, S-5 and the two dimers, and the two dimers could themselves be resolved
in 8 M urea. Sekura et al. (19831 reported that S-l could be separated from the B-
oligomer after exposing the toxin to 5 M urea, the S-l being resolved on an affinity
matrix which will bind the B-oligomer. Capiau et alf (19861 attempted to repeat this
procedure and their results suggested that the B-oligomer was not bound by the
haptoglobulin - Sepharose affinity matrix and that the column eluate contained a mixture
of S-l, S-3, S-4 and S-5, the column only retaining S-2 and S-4 in equal amounts. The
reason for these differences are unknown.
Subunit purification was attempted in this case by exposing the toxin to 6 M
guanidine followed by extensive dialysis against 8 M urea and gel filtration FPLC on a
Superose 12 column. This was partially successful as it appears that the toxin has been
resolved into dimers S-2 and S-4, and S-3 and S-4 and subunits S-l and S-5 on the
basis of their molecular mass and by comparison with the masses of a set of standard
proteins. The yield of protein from the column however was very low and not
sufficiently high to do any subsequent work with. This very low yield is probably due




KINETIC ANALYSIS OF PERTUSSIS TOXIN
4.1.1. INTRODUCTION
As outlined in the introduction pertussis toxin catalyses the ADP-ribosylation of
Gi, the inhibitory regulatory protein of the adenylate cyclase complex (Ui et al. 1985; Ui
et al. 1986). The overall effect of this ADP-ribosylation is to prevent the inhibitory
action of certain hormones upon this complex, which results in an activation of the
catalytic unit with unregulated amounts of cAMP being produced. Pertussis toxin
catalyses the ADP-ribosylation of several other G-proteins, again causing these proteins
to lose their transducing activities (Gilman, 1987; Milligan, 1988).
Gi has been purified to homogeneity from several cell types (Bokoch, et al.
1983; Katada etal. 1983; Katada et al.. 1985). Purification of this protein is complex as
it makes up only one part in 10^ of total cellular protein and is also very labile (Gilman,
1984). As is the case with cholera toxin, additional cofactors may be necessary to
demonstrate pertussis toxin catalysed ADP-ribosylation of purified Gi (Enomoto and
Gill, 1979; Khan and Gilman, 1984). A simple system would therefore be much more
favourable for the kinetic analysis of pertussis toxin. Tamura et al.,(1982); Katada etal.
(1983) and Moss et al„.(1983) demonstrated that pertussis toxin had an NAD+-
glycohydrolase activity, which is not expressed by the toxin in the form by which it is
secreted by B. pertussis, but which can be shown by incubating the toxin with reducing
agents such as dithiothreitol. The NAD+-glycohydrolase activity is the pertussis toxin
catalysed hydrolysis of NAD+ to ADP-ribose and nicotinamide with water acting as the
acceptor of the ADP-ribose moiety. This activity of the toxin is much simpler to study
at the kinetic level than ADP-ribosylation of GTP-binding proteins.
The S-l subunit of pertussis toxin has been shown to be activated in a number
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of ways (Lim et ah 1985: Moss et ah. 1986). The most important of these activating
reagents are the sulphydryl reducing agents. The incorporation of dithiothreitol within
the assay cocktail (at concentrations up to 250 mM), has been shown to increase
nicotinamide release from NAD+. This level of thiol incorporation is the universally
accepted concentration of reducing reagent and results in maximum nicotinamide
production from the pertussis toxin catalysed reaction. This concentration appears
incred high if it is only required within the assay to maintain enzyme activity,
strongly suggesting that it may have another function within the reaction. Moss and
Vaughn (1984) demonstrated that activation would result from incubating the toxin with
20 mM dithiothreitol, again suggesting that the vast excess of reducing reagent may play
an alternative role within the enzyme catalysed process. ATP and the detergent CHAPS
promote the activation of pertussis toxin by DTT (Kaslow et al. 1987). Burns and
Manclark (1986), demonstrated that the combination of ATP and CHAPS causes the
release of S-l from the B-oligomer. These observations suggested that the activation of
pertussis toxin by ATP, CHAPS and DTT may expose the key amino acids of the toxin
essential in the catalytic mechanism. It has also been suggested by Moss et al, (1986)
that membrane phospholipids act synergistically with ATP in the activation of pertussis
toxin.
In order to determine the sites of action of ATP and CHAPS, the S-l subunit
was separated from the B-oligomer by chromatographic methods and the effects of the
two reagents on the isolated active subunit investigated. Only CHAPS was shown to
stimulate the NAD+-glycohydrolase activity of the isolated S-l subunit indicating that
the detergent was directly involved in the activation of S-l. ATP was shown only to
activate the holotoxin; this activation was thought to result from the binding of ATP to
the B-oligomer which in some way caused the S-l subunit to dissociate from the
binding component. Diphtheria toxin has been shown to have a tightly bound
nucleotide (Ap Up), which must be bound to this protein for maximal activation of
enzymic activity. ATP may be acting in an analogous fashion within the pertussis toxin
reaction mixture by mimicking the action of a compound similar to ApUp involved in
the stimulation of the enzymic activity of pertussis toxin.
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Kaslow eLai.^1987) identified three binding sites on the toxin for these
activating substances: (i) the A (adenosine) and P (polyphosphate) sites, these two sites
being involved in the binding of ATP; (ii) the L-site (or lipid site) which binds
activators which are hydrophobic in nature and (iii) the S (sulphydryl) site which leads
to activation of the toxin when it is reduced.
Do these activating agents mimic what is happening in infected cells? Katada et
al,?(1983), suggested that an enzymic mechanism is essential for activation of the toxin
in vivo, this involving either disulphide bond reduction or proteolytic cleavage. This
does not appear to be the case however, since Meister and Anderson (1983),
demonstrated that in the presence of ATP and CHAPS, glutathione could activate
pertussis toxin within the range found in eukaryote cells. This argues that cellular ATP
and membrane lipids could allow intracellular glutathione to activate pertussis toxin by a
non-enzymic procedure within the host cell.
There are two cysteine residues within the S-l subunit and these form a
disulphide bond in the mature toxin (Burns, 1988). It is reduction of this bond which is
essential for toxin activation. Kaslow et al.,119871. suggested that one, or both of these
cysteine residues may be involved directly in the enzyme mechanism of the toxin.
Modification of these two cysteine residues, Cys 41 and Cys 200, resulted in loss of
enzymic activity. To establish which of these cysteine residues is the mod important in
CRH)
catalysis, Kaslow et aD generated a tryptic fragment of the S-l subunit which
contained the first 187 amino acids, therefore not cysteine 200, and demonstrated that
this fragment was enzymically active. This suggests that Cys 41 may be in thdCregion
of S-l which plays a critical role in the enzymic reaction catalysed by the toxin (Locht et
21,1987).
The present trend of thought is that this disulphide bond plays two roles in the
activity of pertussis toxin. Firstly^that the disulphide bond maintains the S-l subunit in
the appropriate conformation enabling it to bind to the B-oligomer and secondly, that it
maintains S-l in an enzymically inactive form. Reduction of this disulphide bond
therefore has two effects both of which result in increased enzymic activity. Reduction
of the bond stabilising an enzymically active conformation which does not reassociate
with the B-oligomer and also exposes Cys 41 and the region surrounding it, this region
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being important in enzymic activity.
Burns et al. (1988) demonstrated that pertussis toxin has many structural
similarities to cholera toxin, which has similar enzymic activities. Regions of amino
acid sequence homology have been found between these toxins (Locht and Keith, 1986;
Nicosia et al. 1986) suggesting that these regions may be involved in the enzymic
reactions of these proteins. These regions are found between amino acids 30 and 58,
including Cys 41, which is further evidence that this residue plays an important role in
the NAD+-glycohydrolase and ADP-ribosyltransferase activities of the toxin.
4.1.2. Kinetic models
In order to evaluate the kinetics of an enzyme catalyzed reaction the kinetic
parameters Km (Michaelis constant) and kcat (the maximum capacity of the enzyme
when substrate is saturating) are calculated.
These constants give an estimate of the kinetics of that reaction under the
conditions likely to be found in vivo. Published values for the pertussis toxin catalysed
NAD+-glycohydrolase reaction differ as a consequence of the degree of activation of the
enzyme. Moss and Vaughn (1984) have demonstrated that maximum NAD+-
glycohydrolase activity is obtained by the addition of 250 mM dithiothreitol within the
assay system. This concentration appears exceptionally high if it is only required to
maintain the toxin within an active conformation, however this is the concentration of
reducing reagent routinely incorporated within the NAD+-glycohydrolase reaction
mixture. This massive concentration suggests an alternative role for these reagents and
this is investigated in this chapter.
Tait and Nassau (1984) developed a model assay system for cholera toxin, using
low molecular weight arginine derivatives as substrates for its ADP-ribosyltransferase
reaction. This assay is similar to that of Moss and Vaughn (1984) in that it measures
toxin activity indirectly by measuring the rate of nicotinamide release from NAD+. This
assay was adapted to investigate potential substrates for pertussis toxin, both those
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which had been shown previously to be substrates for cholera toxin and sulphydryl
group containing compounds. The NAD+-glycohydrolase activity of pertussis toxin
has been previously studied by Moss and Vaughn (1984); Moss et al. (1986) and
Kaslow et al. (1987) who investigated the properties of the different activating reagents
discussed in the introduction to this chapter. In the remainder of this chapter the NAD+-
glycohydrolase activity of the toxin has been further investigated and the mechanism
whereby several sulphydryl-reducing reagents were involved in the assay system
demonstrated in an attempt to gain further information about the nature of this enzymic
activity of this toxin.
4.2. RESULTS
4.2.1. Characterisation of the NAD+-glycohydrolase assay
Preliminary experiments were carried out to check the suitability of the assay for
kinetic measurements. The NAD+-glycohydrolase activity was found to be proportional
to toxin concentration over the concentration range 5-50 pg/ml. The activity was also
dependent upon temperature, with activity increasing between 25°C and 40°C, above
which the activity began to decrease again (Figure 4.1). NAD+-glycohydrolase
experiments were routinely carried out at 30°C.
As outlined in section 2.2.3.2 the toxin must be activated via disulphide bond
cleavage with reducing reagents before it will act as an NAD+-glycohydrolase. Figure
4.2 illustrates how the extent of activation affects the velocity of reaction during the
initial stages of the procedure. However, after 1 hour, presumably as the toxin is in
contact with 250 mM reducing agent within the assay cocktail, the toxin is fully active
catalysing release of nicotinamide at the same rate independent of activation time. A
pre-activation period of 30 minutes in 20 mM dithiothreitol and an assay time of 4 hours









The effect of temperature on the rate of pertussis toxin catalysed
NAD+-glycohydrolase.
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FIGURE 4.2
The effect of pre-activation time on the rate of pertussis toxin
catalysed NAD+-gIycohydroIase.
30 minute pre-activation at 30°C was routinely carried out.
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hour of the assay, demonstrates that once fully active the conditions of the assay do not
change throughout the assay period, therefore there has been no significant depletion,
inactivadon of enzyme, or inhibition of the enzyme with product.
4.2.2. Controls of NAD+-breakdown
As the NAD+-glycohydrolase assay measures the release of nicotinamide from
NAD+ catalysed by pertussis toxin, it is important to include controls to take account of
nicotaminide produced by the non-enzymic breakdown of NAD+. This is a greater
problem when the assay is carried out in buffers of p.H values 7.0 and above,
especially in the presence of phosphate ions (Colowick et al. 1951). However,
phosphate has been shown to promote maximum nicotinamide release from a cholera
toxin catalysed NAD+-glycohydrolase system involving the same assay procedure
(Moss et alf 1976: Tait and Nassau, 1984). The assays were thus performed in a
phosphate buffer system but at the slightly acid p.H of 6.5 to minimise the degradation
of NAD+.
Controls were included for each assay sample, at each concentration of NAD+,
to measure the non-enzymic breakdown of NAD+. These controls contained all of the
assay constituents except enzyme. Non-enzymic breakdown was typically less than 5%
of the total NAD+ added under the conditions of the assay (4 hours at 30°C).
As a final control, paper chromatographic separation of lflCi of both [4-
3H]NAD+ and [3H] nicotinamide was carried out to demonstrate the efficiency of the
Dowex AG-IX resin to separate the reaction products. The experimental procedure is
discussed in section 2.2.3.3. Figure 4.3 shows the results of this separation and
demonstrates that of the [3H] nicotinamide added 92-98% was recovered following
Dowex AG-IX chromatography and of the [4-3H] NAD+, 0.5-0.9% leached off the
column.
FIGURE 4.3
DEMONSTRATION OF THE EFFICIENCY OF THE DOWEX AG-
1X2 RESIN FOR SEPARATING NICOTINAMIDE AND NAD+
2000-i ioooH




4.2.3. Kinetics of the NAD+-glycohydroIase reaction
The rate of [3H] nicotinamide release from [4-3H] NAD+ catalysed by pertussis
toxin was measured at various concentrations of NAD+. The results are presented as
Lineweaver-Burk (Lineweaver et al. 1934). Hanes (Hanes 1932) and direct linear plots
(Cornish-Bowden and Eisenthal, 1978), Figures 4.4, 4.5 and 4.6. The Km values
calculated differed slightly between plots, the results are shown in the Figures. A kcat
of 0.25 min"1 was derived from this data. The kcat value assumes that all of the protein
present is enzyme and that all enzyme is active. This is a valid assumption in this case
as the protein preparation was very pure, containing only pertussis toxin as shown by
SDS polyacrylamide gel electrophoresis, and under the conditions of this assay system
the protein should remain active throughout its duration.
This Km value is also calculated at a dithiothreitol concentration of 250 mM
which has been shown to be required for maximum pertussis toxin NAD+-
glycohydrolase activity (Moss and Vaughn, 1984). Experiments had previously
demonstrated that as more thiol was added to the system, up to these excessively high
concentrations, more nicotinamide was released and 250 mM dithiothreitol became an
accepted constituent of the assay mix.
Moss et al. (1983) investigated the change in rate of nicotinamide release via
pertussis toxin catalysed NAD+ in the presence of a number of reducing reagents and
these results are shown in Table 4.1. The results demonstrate that mercaptoethanol,
dithiothreitol, glutathione and cysteine can all activate pertussis toxin and that increasing
the concentration of any of these reducing reagents, results in increased nicotinamide
release. However, cholera toxin catalysed NAD+-glycohydrolase, which involves
a similar activation procedure, requires only 5 mM of reducing agent (Galloway and van
Heyningen, 1986), this cjjncinWUon 0^ ^cWcav\C\ (xo^q.a^ 10 tvwvc\\ *v\0vSi l^ip'CcA
required for reduction of a disulphide bond. An inVestigation into the effect of the
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FIGURE 4.4
HANES PLOT OF PERTUSSIS TOXIN CATALYSED NAD+-
GLYCOHYDROLASE.
Km = 30 ± 5(iM
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FIGURE 4.5
LINEWEAVER-BURK PLOT OF PERTUSSIS TOXIN
CATALYSED NAD+-GLYCOHYDROLASE.




EISENTHAL CORNISH-BOWDEN PLOT FOR PERTUSSIS
TOXIN CATALYSED NAD+-GLYCOHYDROLASE.
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sulphydryl group was next carried out in order to determine whether these reagents
played any other role within the NAD+-glycohydrolase reaction mechanism apart from
activation.
Table 4.1 Effects of increasing thiol concentrations on release

















4.2.4. Kinetics of NAD+-glycohydrolase reaction with
sulphydryl group as substrate
The amino acid which accepts the ADP-ribose moiety from the pertussis toxin
catalysed ADP-ribosylation reaction has been suggested to be either aspartate (Hurley £t
aL.1984) asparagine (Abood et al.^1982: Manning et al.^1984) or cysteine (West et al ^
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1985). It is now thought most likely to be cysteine. West et ah(1985) demonstrated
that a cysteine residue in transducin is the amino acid which accepts ADP-ribose. This
group sequenced the tryptic peptide of transducin which was ADP-ribosylated by
pertussis toxin and HPLC analysis identified cysteine as the target amino acid. This
being the case the sulphydryl group may be acting as a substrate by accepting the ADP-
ribose, produced by the pertussis toxin catalysed NAD+-glycohydrolase reaction.
To investigate this possibility some basic enzyme kinetics were initially carried
out with the sulphydryl group as the variable. The initial velocity of [3H] nicotinamide
release from NAD+ was measured at a saturating NAD+ concentration of 100 |iM and at
various concentrations of sulphydryl reagent. The reagents used were dithiothreitol,
cysteine, mercaptoethanol and glutathione. The results are shown as Hanes and direct
linear plots in Figures 4.7 - 4.14. In all cases increasing concentrations of thiol
increased the rate of reaction until saturation was achieved. From conventional enzyme
kinetic analysis of the effects of these sulphydryl reagents at fixed NAD+ concentration,
Km values for the sulphydryl groups were calculated. The estimated Km values from
Hanes plots were 105 mM for cysteine, 127 mM for dithiothreitol, 110 mM for
mercaptoethanol and 102 mM for glutathione. This indicates that the sulphydryl
reagents are acting as substrates for the reaction.
4.2,5. Isolation of an ADP-ribose-sulphydryl compound
The ADP-ribosylation reaction was carried out as previously described with 100
|iM NAD+ and 250 mM cysteine in the final reaction mixture. The reaction products
were filtered to remove all traces of protein and loaded onto an HPLC system. The
column used was a reverse-phase ODS-HYP 2734 column (25cm by 4.6mm), the
mobile phase was 90% (v/v) 10 mM NH4H2PO4, 10% (v/v) methanol, p.H 3.5 which
was run at a flow rate of 1 ml/min, using Altex equipment. The absorbance of the eluate
was monitored at 254 nm.
Figure 4.15 shows the separation by HPLC of standard solutions of ADP-
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FIGURE 4.7
HANES PLOT OF PERTUSSIS TOXIN CATALYSED NAD+-
GLYCOHYDROLASE WITH CYSTEINE AS SUBSTRATE.
Km = 105mM
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FIGURE 4.8
EISENTHAL CORNISH-BOWDEN PLOT FOR PERTUSSIS
TOXIN CATALYSED NAD+-GLYCOHYDROLASE WITH
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HANES PLOT OF PERTUSSIS TOXIN CATALYSED NAD+-
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FIGURE 4.11
HANES PLOT OF PERTUSSIS TOXIN CATALYSED NAD+-
GLYCOHYDROLASE WITH MERCAPTOETHANOL AS
SUBSTRATE.
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FIGURE 4.12
EISENTHAL CORNISH-BOWDEN PLOT FOR PERTUSSIS
TOXIN CATALYSED NAD+-GLYCOHYDROLASE WITH
MERCAPTOETHANOL AS SUBSTRATE.
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FIGURE 4.13
HANES PLOT OF PERTUSSIS TOXIN CATAUYSED NAD+-
GLYCOHYDROLASE WITH GUUTATHIONE AS SUBSTRATE.
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ribose, NAD+, AMP and nicotinamide. Nicotinamide absorbs very weakly at 254 nm,
so the concentration of the standard nicotinamide solution was made 10 times greater
than that of the other compounds. The products of the above enzyme catalysed reaction
(100 |iM NAD+ in the presence of 250 mM cysteine for 4 hours at 30°C) were applied
to the column and ADP-ribose and NAD+ could be identified from the absorbance trace
of the eluate. Figure 4.16 shows the HPLC trace obtained from the reaction products.
As mentioned earlier in this section, nicotinamide absorbs very weakly at 254nm and is
also much retarded in this system. This makes nicotinamide very difficult to detect
using this HPLC system and, in fact impossible at the very low concentrations
produced by the pertussis toxin catalysed reaction. Cysteine does not absorb at 254 nm
and cannot be detected from the trace. The final reaction product cannot be identified by
comparison with the standard trace. This reaction product may be the ADP-ribosyl
cysteine suggested from the kinetic data as its elution position is compatible with that
assumption. When isolating the ADP-ribosyl-cysteine produced from the pertussis
toxin catalysed ADP-ribosylation of transducin, West et alA 19851 showed that this
product was eluted between ADP-ribose and NAD+ when using a very similar HPLC
system.
To confirm the identities of the reaction products, radioactively labelled
compounds [adenine-2,8-3H] NAD+ (2.5 jlCi mmol"1 in the mixture) and [14C(U)]
cysteine (1.3 (iCi-mmol"1) were incorporated into the reaction mixture. The ADP-
ribosylation reaction procedure was repeated as above and the filtered solution applied
to the HPLC column. Eighty x 5 drop fractions (total volume about 0.5 ml) were
collected from the column and each fraction assayed for both 3H and 14C radioactivities.
Figure 4.17 shows the results. By comparing the radioactivity in each fraction with the
HPLC trace of the reaction products it is clear that the unknown reaction product
contains both 14C and 3H, and so is compound containing both cysteine and the adenine
moiety of NAD+. This peak was collected from many HPLC runs, freeze dried to
concentrate the compound, resuspended in the HPLC buffer and Figure 4.18a shows
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an HPLC run of the isolated assay product.
4.2.6. Treatment with phosphodiesterase
If the unknown compound is ADP-ribosyl-cysteine, then treatment with snake
venom phosphodiesterase should release AMP and phosphoribosyl cysteine as reaction
products. A sample of the purified material (as shown in Figure 4.18a) was incubated
with a phosphodiesterase from Crotalus durissus terifficans (20|ig/ml) in 50 mM
phosphate buffer p.H 7.5, for 5 hours at 37°C. The products of the phosphodiesterase
reaction were filtered and applied to the HPLC column. Figure 4.18b shows the trace
obtained demonstrating that AMP has been released by the action of phosphodiesterase,
Figure 4.18c showing the proposed enzymic reaction. The other reaction product
identified from this trace was a small amount of the starting material. Phosphoribosyl-
cysteine does not absorb at 254 nm so its elution position could not be determined from
the HPLC trace.
The isolated ADP-ribosyl-cysteine reaction product is radioactive, being labelled
with both 14C on the cysteine moiety and 3H on the adenine constituent of this product.
In an attempt to locate phosphoribosyl cysteine the phosphodiesterase reaction was
repeated and 90 x 10 drop fractions were collected from the column, directly into
scintillant, and each fraction counted for both 14C and 3H radioactivities. As the total
amount of radioactivity applied to the column was small, the differences between each
fraction were not great, but sufficient to identify several peaks of radioactivity. The
results are shown in Figure 4.19. The peaks of radioactivity identified were:
(i) 3H and 14C peak corresponding to the starting material
(ii) 3H peak corresponding to AMP
(iii) 14Cpeak
The final 14C peak was eluted at a
position compatible with it being phospho-ribosyl-cysteine.
FIGURE 4.15
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4.2.7. Investigation of other putative substrates
Hurley et aL/1984). suggested that the amino acid which accepts the ADP-ribose
moiety from the pertussis toxin catalysed ADP-ribosylation was aspartate. Abood et al
(1982) and Manning et ah (19841 disputed these findings and suggested that the receptor
amino acid was asparagine. West et al (1985). demonstrated it was a cysteine residue
within transducin which accepts ADP-ribose from the pertussis toxin catalysed ADP-
ribosylation of this protein. In an attempt to determine whether the NH2 group could
act as ADP-ribose acceptor from the pertussis toxin catalysed reaction, the effects of
two artificial substrates designed for cholera toxin were investigated. These compounds
were designed to mimic the arginine acceptor group on Gs which is covalently modified
by cholera toxin catalysed ADP-ribosylation. Figure 4.20 shows the structures of
arginine and asparagine and the two artificial substrates used; AbOS^lb-
(acetylamino)decyl]guanidine and A599; [12-(phenyl methylamino)]dodecanyl
guanidine. The NAD+-glycohydrolase procedure previously described was repeated
with the addition of 2 mM A603 or A599 and the results obtained are shown in Figures
4.21 and 4.22. Both artificial substrates had negligible effect on the rate of NAD+
hydrolysis indicating that neither were acting as a substrate for the toxin.
4.3. DISCUSSION
The results from the experiments described in this chapter provide some
additional information about the NAD+-glycohydrolase reaction catalysed by pertussis
toxin.
NAD+ + H20 > ADP-ribose + nicotinamide + H+
The rate of reaction was measured as nicotinamide release from NAD+ with
adequate controls being carried out to demonstrate that the breakdown of NAD+ was an
enzymic process with water acting as the acceptor of ADP-ribose. Michaelis constants
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were calculated from Lineweaver-Burk, Hanes and direct linear plots. The Km values
differed slightly between plots. The Lineweaver-Burk plot is commonly used to
represent kinetic data but is not recommended as it gives a misleading impression of
experimental error. This plot 15 \W double-reciprocal plot of 1/[S] versus 1/v .
misinterpretation of error results from small values of v, with little error in measurement
leading to enormous errors in 1/v, but for large values of v, these same small errors in
measurement lead to barely noticeable errors in 1/v. The Hanes plot, of [S]/v versus
[S], is a much better plot as over a fair range of [S] values the errors in [S]/v provide a
faithful reflection of the errors in measurement of v. Finally, the direct-linear or
Eisenthal and Cornish-Bowden plot of v versus [S] in which pairs of v and [S] values
are joined, with each line representing one observation, provides another method of
representing kinetics. If no error occurred in measurement each line representing a
single determination of v at a particular value [S] would intersect at a common point,
this point defining the values of Km and Vmax. This is very rarely the case as in nearly
every experimental procedure there will be some error in measurement. The median
intersection point is then used to determine Vmax and Km, this point being when the
lines crowd closest together. The median value is used in preference to the mean as the
median values avoids bias through extreme values.
The Michaelis constant of 30 ± 5|lM calculated from the Hanes plot for pertussis
toxin catalysed NAD+-glycohydrolase agrees well with published results (Moss and
Vaughn, 1984; Burns and Mandark, 1986; Kaslow et al..19871 and was calcuWleJat a
dithiothreitol concentration of 250 mM. The kcat derived from these results was 0.25
min"1. This is quite a low value, as would be expected for this reaction since the NAD+-
glycohydrolase activity is secondary to ADP-ribosylation with H20 being a poor
substrate for the reaction. NAD+-glycohydrolase only occurs in the absence of GTP-
binding regulatory protein substrates.
The very high concentration of reducing agent incorporated within the assay
presumably maintains the toxin in such a conformation as to maintain maximum
enzymic activity throughout the duration of the assay. As previously stated the
concentration of thiol required to activate cholera
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toxin NAD+-glycohydrolase is 5 mM, a concentration typical of that required for
enzymic activity after reduction of an essential disulphide bond. The concentration used
here (250 mM) was thought to be excessive if the reducing agents were only required
for enzyme activity, and their role as possible substrates was investigated. The rate of
nicotinamide release was thus measured at increasing thiol concentrations (at saturating
levels of NAD+) in order to determine whether these potential substrates would undergo
enzyme kinetic analysis. The four sulphydryl reagents used were dithiothreitol,
cysteine, mercaptoethanol and glutathione. In all cases, increasing the concentrations of
these reagents increased the rate of reaction until saturation was achieved at
concentrations of the order of 300 mM, suggesting that the thiols were substrates. The
Km calculated for cysteine at saturating concentrations of NAD+ was 105 mM and that
calculated for the other reagents were within the same range. The Km values are very
high, but the values calculated demonstrate that the thiols can be substrates at the
concentrations used within the NAD+-glycohydrolase protocol (Moss et al. 1983: Moss
et al.^ 19841. The order of substrate preference for pertussis toxin would be G-
proteins, H20 and finally the sulphydryl group of reducing reagents.
By using NAD+ and cysteine labelled with different radionucleotides the
formation of a compound containing both the adenine moiety of NAD+ and the carbon
atoms of cysteine has been identified as a reaction product from the pertussis toxin
catalysed reaction -
NAD+ + H20 + cysteine > ADP-ribose + nicotinamide +
ADP-ribosyl-cysteine + H+
Although this does not prove a definite structure for this compound, it is
reasonable to propose that the compound formed is ADP-ribosyl-cysteine with a
covalent bond between the C-l atom of ribose and the sulphur atom of cysteine as
shown in Figure 4.23.
The reaction product was isolated by HPLC and treated with a snake venom
FIGURE 4.23
PROPOSED REACTION MECHANISM OF ADP-RIBOSYLATION
REACTION WITH CYSTEINE AS SUBSTRATE SHOWING THE




















































phosphodiesterase which liberated AMP, as would be predicted if the reaction product
was ADP-ribosyl-cysteine. Cysteine has been identified as the amino acid which
accepts the ADP-ribose moiety from the pertussis toxin catalysed ADP-ribosylation of
transducin by West et al.;1985. who also demonstrated that the ADP-ribosyl-cysteine
formed was eluted between ADP-ribose and NAD+ from a similar HPLC system, at the
same position as the ADP-ribosyl-cysteine reaction product from the pertussis toxin
catalysed NAD+-glycohydrolase reaction.
These experiments show that thiols can have two roles in the activity of
pertussis toxin in vitro: as an activator of the toxin, at lower concentrations, by
reduction of a disulphide bond, and as a weak substrate for the ADP-ribosylation
reaction at high concentrations.
As previously discussed it had been suggested by Abood et al. (19821 and
Manning et al l 19841 that asparagine was the amino acid which accepts the ADP-ribose
from the pertussis toxin catalysed ADP-ribosylation. It is generally believed that this
residue is in fact cysteine, with the previous work discussed in this chapter adding to
the evidence. However, to determine whether the NH2 group of asparagine could act as
a substrate the artificial substrates designed for cholera toxin were incorporated into the
reaction and their effect on the kinetics determined. The two reagents used 0J ere firstly
A599, a small guanidine derivative with a polar head group, separated from a charged
end group by an unknown length of carbohydrate chain (Tait and Nassau, 1984), and
secondly A603 which is a similar compound having a polar head group, hydrocarbon
chain and a charged end group. Both of these reagents had no effect on the pertussis
toxin catalysed NAD+-glycohydrolase reaction suggesting that the NH2 group does not
act as a substrate for pertussis toxin within this in vitro system.
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CHAPTER 5
BINDING OF NAD+ TO PERTUSSIS TOXIN
5.1. INTRODUCTION
Binding of ligand to protein is the primary step in all enzyme catalysed
reactions. Once the substrate ligand has bound to the enzyme, the enzyme can launch
its catalytic conversion. In chapter 4 a Km of 30 + 5|_iM was calculated for the NAD+-
glycohydrolase activity of pertussis toxin. This implies that the binding affinity of the
toxin for NAD+ should be of the same order of magnitude as the Km. Many
experimental methods have been devised for measuring ligand-protein binding. For
soluble protein - ligand systems the method most extensively used is equilibrium
dialysis (Osbourne, 1906).
The number of binding sites on S-l for NAD+ has not been measured. It is
reasonable to suppose that the toxin has one binding site for NAD+ as it seems unlikely
that the protein would have evolved separate catalytic sites for the NAD+-
glycohydrolase and ADP-ribosyltransferase activities, as they are essentially the same
reaction. There is also no evidence for any replication in amino acid sequence indicative
of two or more NAD+-binding sites, however, this one binding site assumptions needs
to be confirmed. Poly (ADP-ribosyl) transferase enzymes isolated from the eukaryote
nucleus have been shown to contain both an initial catalytic site and one or more
different acceptor sites (Bauer and Kun, 1984; Kawaichi et al. 1981). These reactions
involve the binding of two or more molecules of NAD+ resulting in the formation of a
poly-ADP-ribose molecule.
The stoichoimetry of binding must be determined in order to characterise any
binding interaction. The maximum number of moles of ligand bound per mole of
protein (n), and the equilibrium dissociation constant Kd were calculated in this chapter
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by the techniques of equilibrium dialysis and quenching of intrinsic fluorescence. The
mathematical description of equilibrium in the simplest case of protein P and ligand L is
given by :
, fL
^ = lEi \u
[PL]
If the number of moles of L bound per mole of protein P is defined as n then
- concentration of TL1 bound to protein
total concentration of all forms of P
[pi ru
[P] + [PL]
l\OUs \(QW QQvACvXr^VN \.[PL1" CpKl]




n = [LJ -
Kd + [L] <*-.
The above equations apply only in the case when n < 1 and is the fractional saturation of
sites. This model assumes that one of P can bind one mole of L and that there is no
cooperation on binding of substrate.
Two types of experimental procedures have been used to calculate the
stoichoimetry of NAD+-binding to pertussis toxin. Firstly a separation method in
which the protein-ligand system is physically separated from free ligand at equilibrium.
This equipment enables direct measurements of bound ligand at equilibrium to be made
without disturbing the system. Equilibrium dialysis is the method used in this case.
Equilibrium can be measured accurately using this method as free ligand L and
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fractional saturation, n can be measured independently.
The second method involves the application of some measurable change in
protein and ligand characteristics on binding of ligand to protein. The most commonly
used techniques are spectroscopic measurements of changes in absorbance,
fluorescence or optical rotary dispersion. These techniques are very sensitive and can
provide information on both Kd and the nature of the protein-ligand complex rapidly
and without disturbing the equilibrium of the system.
5.2. RESULTS
5.2.1. The principles of equilibrium dialysis
Within the equilibrium dialysis chamber a solution of protein on one side of a
semi-permeable membrane is allowed to reach equilibrium with ligand in the same
solvent on the other side (Figure 5.1). At equilibrium the chemical potential of free
ligand [L] must be the same on both sides of the membrane. Protein concentration
should be sufficiently high to enable direct measurement of bound ligand, but not
excessively high as this would result in free ligand depletion and could disrupt the
equilibrium of the system by setting up a potential gradient causing a loss of free ligand
in the protein chamber. If the amount of ligand in the system is greater than the amount
of protein this should not be a problem. The total amount of ligand added to the system
is known and the free ligand concentration can be calculated from the system, then the
amount of ligand bound to protein (n) can be calculated. This can be shown
mathematically as:
n = Lp 3.
PT
When Lp is the number of moles of ligand bound to protein.
PT is the total number of moles of protein.
LT is the total ligand.
[L] is free ligand then:
Lp = Lp - VT [L]
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Where V-p is the total volume of solution in both compartments.
In most situations some free ligand will bind to the dialysis apparatus - therefore Lp
is expressed as:
Lp = frr-VT[L]-LM 5.
If necessary correction must be made for in calculations.
As protein itself carries a net charge, and the ligand of interest in this system,
NAD+, also carries a net charge, then even in the absence of binding the concentration
of free ligand may not be the same in both compartments because of the Donnan effect
(Donnan, 1924). This difference in concentration can however be made negligible by
ensuring that the buffer used within the system is of a sufficiently high ionic strength.
At high protein concentrations, relatively high concentrations of a supporting electrolyte
may be required within the system to render the Donnan effect negligible.
Equilibrium dialysis was carried out using a Dianorm equilibrium dialysis
apparatus. This system consists of an array of teflon cells in a rotating assembly. Each
cell is made up of two half cells, which are separated by a dialysis membrane, with
ports on both sides for the loading and unloading of samples. This apparatus allows a
quick and reproducible estimates of both Kd and n (Weber et al^ 19601. A number of
preliminary experiments were performed to characterise the system in terms of
equilibrium time, stability of protein and ligand etc., and these are described below.
5.2.2. Dialysis time
The time taken to reach equilibrium under the conditions outlined in section
2.2.3 was determined by the time taken for solutions of [4-3H]NAD+ (20 nCi)

























regular time intervals over a period of 5 hours at 30°C, and the radioactivity counted.
Equilibrium was reached after 180 minutes as shown in Figure 5.2.
5.2.3 Recovery of radioactivity
When [4-3H]NAD+ was dialysed against pertussis toxin (1.5 mg/ml)
comparison of the total amount of radioactivity added with the amounts found in 100 |il
aliquots taken from each half cell during dialysis, showed that more than 95% of the
total radioactivity was recovered. The small loss of radioactivity was most probably
caused by ligand binding to the dialysis membrane and the teflon cell.
5.2.4. Non-specific breakdown of NAD+
To determine the integrity of NAD+ after dialysis against pertussis toxin,
samples were removed at the end of each experiment and were analysed by paper
chromatography as described in section 2.2.3.3. In all cases less than 5% of the NAD+
had broken down to nicotinamide. This indicates that unlike diphtheria toxin, which
can completely hydrolyse a ten fold molar excess of NAD+ within two hours (Kandel et
al, 1974), the NAD+-glycohydrolase activity of pertussis toxin should not complicate
the dialysis experiments.
5.2.5 Binding experiments
Experiments were carried out using pertussis toxin at concentrations in excess of
1 mg/ml (1 x 10~9 moles^OO |il) and 1 - 200 |iM NAD+ containing 20 nCi [4-3H]
NAD+. A high protein concentration was used so that sufficient ligand was bound to
the protein, enabling accurate measurements of free ligand concentration and therefore











PRELIMINARY EXPERIMENT FOR DETERMINATION OF TIME
TAKEN FOR EQUILIBRIUM DIALYSIS SYSTEM TO REACH
EQUILIBRIUM.
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buffer containing 1 M urea. The urea was necessary as pertussis toxin is notoriously
insoluble in most aqueous systems. As will be discussed in a later section in this
chapter, circular dichroism analysis of the toxin demonstrates that the structure of the
toxin in unaffected in this solution, therefore urea at this concentration should not affect
binding. The buffer used was 0.1M NaCl, 0.01M K2HP04, pH 7.2, 1M urea. The
relatively high concentration of supporting electrolyte, NaCl, ensures that the Donnan
effect is negligible within this system (van Holde, 1971).
Experiments were carried out at a number of different temperatures; 7°C, 23°C,
30°C, 37°C, 40°C and 50°C. Typical graphs are shown in Figures 5.3- 5.7 and also in
Appendix j as plots of 1/n versus 1/[L], double reciprocal plots of moles of ligand
bound per mole of protein (n) versus free ligand concentration (n) (Hughes-Klotz plot),
being used in preference to the more familiar Scatchard plot (Scatchard, 1949).
Logarithmic plots demonstrating saturation are shown in Figures 5.8 and 5.9.
The binding parameters are summarised in Table 5.1 and from these results at
different temperatures some basic thermodynamic parameters could be obtained. The
van't Hoff Isochore shown in Figure 5.10 gives calculated enthalpy change AH of
30 kjoules. mol'1 for the binding of NAD+ to pertussis toxin. This is a typical value for
an enzyme-ligand interaction.
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FIGURE 5.3
EQUILIBRIUM DIALYSIS SYSTEM AT 7°C
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FIGURE 5.5
EQUILIBRIUM DIALYSIS AT 23°C
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FIGURE 5.6
EQUILIBRIUM DIALYSIS AT 30 °C
Kd = 24 ± 3|iM
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EQUILIBRIUM DIALYSIS AT 40°C
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FIGURE 5.8
LOGARITHMIC PLOT OF NAD+-BINDING TO PERTUSSIS
TOXIN AT 20°C
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FIGURE 5.9
LOGARITHMIC PLOT OF NAD+-BINDING TO PERTUSSIS
TOXIN AT 30°C
Kd AT THE POINT OF INFLECTION = 25^M
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FIGURE 5.10
van't HOFF ISOCHORE FOR NAD+-BINDING TO PERTUSSIS
TOXIN AT 30°C
AH = 30 kJoules.mol"1
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TABLE 5.1 Binding parameters calculated by equilibrium dialysis
and fluorescence.
1. Equilibrium dialysis
Temperature Kd ((J.M) No. of binding sites (n)
7°C 90 ±5 3-0. 1.15 ±0.05 ^.0
20°C 40±5 3.0. 1.10 ±0.05
23°C 35 ±2 3.0. 1.10 ±0.20 3.0.
30°C 24±2 5.0. 1.00 ±0.10 5.0.








5.2.6. Quenching of protein fluorescence by NAD+
Fluorescence spectroscopy was an alternative approach used to study this toxin-
ligand interaction. This method was previously used by Kandel et al. (1974) and by
Chung and Collier, (1977) to study the binding of NAD + to diphtheria toxin fragment A
and Pseudomonas aeruginosa exotoxin A respectively. The binding of NAD+ causes a
quenching of intrinsic fluorescence (excitation 285, emission 333 nm) of both these
toxins. The intrinsic fluorescence of diphtheria toxin fragment A was reduced by up to
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60% while that of exotoxin A was reduced by 20%. In both cases the concentration of
NAD+ which gave half maximal quenching was about 9 pM, a value which correlated
well with the Km values of 8 |lM calculated for the NAD+-glycohydrolase activities of
both toxins. This quenching is thought to result from formation of a charge transfer
complex between the nicotinamide moiety of NAD+ and a tryptophan residue within
each of the toxins.
A catalytically active peptide of pertussis toxin S-l subunit, the CI 80 peptide,
has been engineered to facilitate investigation into the catalytic site of the protein
(Barbieri et al.^1989: Cortina and Barbieri, 1989). Site directed mutagenesis of Trp26
was carried out with the tryptophan residue being replaced with aspartic acid or
asparagine. The substituted peptides were assayed for NAD+-glycohydrolase activity
and the rate of NAD+ hydrolysis was less than 1% of the native CI80 peptide.
Phenylalanine and tyrosine substitution gave smaller reductions in the rates of NAD+
hydrolysis, 6 - 20% of that of the native peptide respectively. This tryptophan residue
appears to have an analogous function to the tryptophan residues involved in the
efficient binding of NAD+ to diphtheria toxin fragment A and pseudomonas aeroginosa
exotoxin A, which suggests that the intrinsic fluorescence of pertussis toxin could be
used to determine its NAD+ binding parameters.
When pertussis toxin is excited at 285 nm, the emission spectrum shows tuo
peaks, one at 307 and the other at 338 nm. The S-l subunit has been shown to contain
18 tyrosine residues (Locht and Keith, 1986; Nicosia et al. 19861. Tyrosine residues
fluoresce at ~ 305 nm when excited at 280 nm, suggesting that the first peak is as a
result of tyrosine fluorescence. The maximum at 338 nm therefore corresponds to
tryptophan fluorescence. Titrations were carried out at 280 nm excitation and 333 nm
emission (see Figure 5.11 for fluorescence difference spectra of 10 mM potassium
phosphate, 0.1 M NaCl pH 7.2 buffer versus 0.1 mg/ml pertussis toxin in the same
buffer between 290 and 380 nm. )
Wavelength (nm)
FIGURE 5.11
FLUORESCENCE DIFFERENCE SPECTRA OF lOmM
POTASSIUM PHOSPHATE, 0.1M NaCI pH7.2 versus 0.1m
PERTUSSIS TOXIN IN THE SAME BUFFER BETWEEN 290
AND 380nm.




In equilibrium dialysis free ligand concentration and protein-ligand complex
could be measured directly at equilibrium. From these values the fractional saturation,
n, was determined. Fluorescence, on the other hand, provides an indirect method of
determining fractional saturation. In this case we have assumed that the reduction in
fluorescence at 280 nm excitation, 333 nm emission can be correlated to n, a valid
assumption as titrations show saturation at higher concentrations of NAD+ and the
values derived for Kd are in close agreement with those from equilibrium dialysis. This
technique for determining binding parameters assumes that it is only the protein which
fluoresces at the wavelengths involved. This is not the case and correction factors have
been calculated to take into account the contribution made by NAD+ (inner filter
effects). This has been done by two methods. Firstly, a solution of tryptophan, of the
same initial fluorescence as the toxin solution, was titrated with NAD+ and secondly, by
the method of Honore and Pedersen (1989). This second method involved the
following correction factor:
Aemmis = Absorbance 285 nm
Aecit = Absorbance M 3 nm
contribution made by UV absorption at the emission and excitation wavelengths.
Fractional saturation was then calculated as follows:
and accounts for the




R = 1+ Kd
IL]
A plot of 1/n versus 1/[L] should give a straight line with slope Kd. The change in
relative fluorescence intensity can be substituted for n as shown in the following
equation:
1 = 1 + Kd /
f fmax [L]
where fmax is the maximum change in relative
fluorescence intensity when toxin is saturated with NAD+ is the change in relative
fluorescence intensity at a particular concentration of [L],
Titrations were carried out as outlined in section 2.2.3.10. at 20°C, 30°C and
40°C, the results are shown in Figures 5.12, 5.13 and 5.14 These plots show that
saturation with NAD+ has occurred at about 80 jiM NAD+ and the concentration of
NAD+ which results in half maximum quenching of fluorescence is 43 |iM at 20 °C, 27
|iM at 30°C and 20 (iM at 40°C. 1/AF versus 1/[L] plots are shown in Figures 5.15,
5.16 and 5.17 where the Kd values are calculated from the intersections on the X-axes.
These Kd values are very similar to those estimated by equilibrium dialysis at the
temperatures studied.
5.2.8 Circular dichroism
As outlined in section 5.2.5., equilibrium dialysis was carried out in
phosphate/NaCl buffer containing 1 M urea. In order to determine whether this urea
concentration had any effect upon the tertiary structure of the toxin, and therefore the
nature of the NAD+-binding site, the technique of circular dichroism was employed.
This would illustrate any change in protein tertiary and secondary structure resulting
from exposure to 1 M urea.
Circular dichroism spectra were obtained from pertussis toxin solutions in the
[NAD] (|iM)
FIGURE 5.12
FLUORESCENCE TITRATION OF PERTUSSIS TOXIN
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FLUORESCENCE TITRATION OF PERTUSSIS TOXIN
INTRINSIC FLUORESCENCE WITH NAD+ AT 40°C.
Kd = 20|iM
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FIGURE 5.15
DOUBLE RECIPROCAL PLOT FOR FLUORESCENCE
TITRATION AT 40°C.
Kd = 20|iM
1/ [NAD ] (hM)
FIGURE 5.16
DOUBLE RECIPROCAL PLOT FOR FLUORESCENCE
TITRATION AT 30°C.
Kd = 28(iM
0.00 - i I 1 I 1 I
0.0 0.1 0.2 0.3
1/ [NAD J (jiM)
FIGURE 5.17
DOUBLE RECIPROCAL PLOT FOR FLUORESCENCE
TITRATION AT 20°C .
Kd = 40(iM
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presence and absence of urea. Traces were from both the near ultra-violet (300 - 250
nm), Figure 5.18 and the far ultra-violet (200 - 250 nm), Figure 5.19 and 20. Figure
5.21 and Figure 5.22 show buffer blanks (10 mM potassium phosphate 0.1 M, NaCl,
pH 7.5; 1 M urea buffer or 10 mM potassium phosphate, 0.1 M, NaCl, pH 7.2),
which were subtracted from the spectra obtained from the toxin. Changes in tertiary
structure is shown by near UV. Circular dichroism scans and far UV scans will show
changes in secondary structure. The pathlength of the near UV cell was 1 cm and that
of the far UV cell was 0.02 cm. Each scan took 5 minutes at a rate of 10 nm/minute.
Each trace represents the average of four scans. Urea was shown to have negligible
effect upon the tertiary structure of the protein within the error limits of the CD
instrument. This is verified by the results gained by fluorescence which shows an
identical Kd value for the binding of NAD+ to the toxin, confirming that the nature of
the NAD+ binding pocket has not been altered. This was as expected as concentrations
of greater than 2 M urea have been previously shown to be necessary in order to
dissociate S-l from the holotoxin (Rappuoli and Silvestri, 1987). From the CD traces
we assumed that 1 M urea had no effect upon binding of NAD+ to pertussis toxin.
5.3. DISCUSSION
In this chapter the binding of NAD+ to pertussis toxin has been studied by two
different methods, firstly by the direct method of equilibrium dialysis and secondly,
indirecdy by titration of the proteins intrinsic fluorescence with NAD+. The Kd values
derived using both techniques were in close agreement and correlated well with the Km
value calculated in chapter 4 for pertussis toxin NAD+-glycohydrolase activity. It has
also been shown that the number of binding sites for NAD+ per toxin molecule is one.
FIGURE 5.18
FAR ULTRA-VIOLET CIRCULAR DICHROISM FOR
PERTUSSIS TOXIN IN lOmM POTASSIUM PHOSPHATE, O.IM
NaCl, pH 7.2 BUFFER (mr 3pt 161) AND IN lOmM POTASSIUM





NEAR ULTRA-VIOLET CIRCULAR DICHROISM TRACE FOR
PERTUSSIS TOXIN IN lOmM POTASSIUM PHOSPHATE, 0.1M
NaCl, pH 7.2 BUFFER (mr 5pt 161) AND IN lOmM POTASSIUM




SUPERIMPOSITION OF FAR ULTRA-VIOLET CIRCULAR
DICHROISM TRACES OF PERTUSSIS TOXIN IN lOmM
POTASSIUM PHOSPHATE, 0.1M NaCl, pH 7.2 BUFFER AND
IN lOmM POTASSIUM PHOSPHATE, 0.1M NaCl, 1M UREA pH
7.2 BUFFER.
mr 5pt 161
mr 6pt 161 pertussis toxin in lOmM potassium phosphate,




pertussis toxin in lOmM potassium phosphate,











BLANK CIRCULAR DICHROISM TRACE FOR BUFFERS IN
THE NEAR ULTRA-VIOLET.
4 blank lOmM potassium phosphate, 0.1M NaCl, pH 7.2
buffer








BLANK CIRCULAR DICHROISM TRACE FOR BUFFERS IN
THE FAR ULTRA-VIOLET.
5 blank lOmM potassium phosphate, 0.1M NaCl, pH 7.2
buffer
6 blank lOmM potassium phosphate, 0.1M NaCl, 1M urea ph
7.2 buffer.
THE TRACE BECOMES VERY NOISY AFTER 200nm, SO FAR











The first technique employed for binding studies was equilibrium dialysis. This
is the simplest method of measuring protein-ligand binding in soluble systems.
However, Kandel et al (1974) demonstrated that this method was not suitable for
determining NAD4" binding to diphtheria toxin. This was a consequence of the
hydrolysis of NAD4" by diphtheria toxin, which was sufficiently rapid to prevent the use
of equilibrium dialysis to measure NAD4" binding to this toxin. This was not the case
for pertussis toxin as the NAD+ase activity was negligible under the conditions used
and the NAD+-glycohydrolase activity is a very inefficient reaction (kcat 0.25 min"1)
even when the toxin is fully activated. However, the negligible breakdown of NAD4" is
probably as a consequence of the lack of reducing agent within the dialysis mixture thus
maintaining the inactivity of the protein. This is an interesting phenomenon as the
binding results show that NAD4" will bind to the toxin even if the protein is not in its
active conformation, suggesting the existence of a ligand binding site and a separate
catalytic site. The results also suggest that NAD4" binds to the inactive form of the
enzyme as well as it would to the active form as the Kd value calculated is very similar
to the Km value and the binding results exhibit saturation at levels of NAD4" which were
shown to be saturating on enzyme kinetic analysis.
Several Kd values were obtained for binding of NAD4" to pertussis toxin, each
at a different temperature, and from these values, a value of the enthalpy change on
binding of NAD4" to the toxin of 30 kjoules.mof1 derived.
The greatest source of error with equilibrium dialysis is the insolubility of
pertussis toxin at the high concentrations of protein required for dialysis experiments.
This was overcome by the incorporation of 1 M urea within the dialysis buffer, which
enabled protein concentrations of greater than 1 mg/ml to be used. This urea
concentration was shown to have negligible effect upon the tertiary structure of the
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protein and as such would probably not cause any change in the nature of the toxins
NAD+-binding site. This higher protein concentration enabled accurate and
reproducible calculation of free-ligand concentration.
5.3.2. Calculation of constants
The results from equilibrium dialysis are shown graphically as plots of 1/n
versus 1/[L], a double reciprocal plot of moles of ligand bound per mole of protein (n)
versus free ligand concentration - a Hughes-Klotz plot in preference to the more
familiar Scatchard plot (Scatchard, 1949). Nimmo et al. (19771 reviewed a number of
methods for analysing data obtained from experiments of similar design to those
described in this chapter, and concluded that the regression of 1/n versus 1/[L] was
preferred because it gave estimates that were accurate, precise and symmetrical in
distribution. This plot is loosely equivalent to the Lineweaver-Burk plot of enzyme
kinetics (Lineweaver and Burk, 1934) a plot which is not favoured by many workers,
as outlined in chapter 4, because of the unequal distribution of errors it produces. It has
been suggested that the differences in suitabilities of the double reciprocal plot between
the two different situations is because in enzyme kinetics one of the variables, substrate
concentration, is a fixed parameter and as such is free of error, whereas in equilibrium
dialysis both of the derived variables, n and [L] are subject to experimental error which
differs for each ligand concentration (Nimmo etal,^ 1977).
5.3.3. Intrinsic fluorescence
Measurement of the changes in the intrinsic fluorescence of pertussis toxin
provided another method of determining binding of ligand to protein. Tryptophan has
been shown to fluoresce at 333nm when excited at 280 nm and it has also been shown
using a model compound, indolyl ethyl-nicotinamide, that the fluorescence of the
indolyl ring is completely quenched by its combination with nicotinamide. Kandel et al.
(1974) and Chung and Collier (1977), used this observation to determine NAD+
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quenching of diphtheria toxin fragment A and Pseudomonas aeruginosa exotoxin A
intrinsic fluorescence. This quenching in fluorescence is thought to result from
formation of a charge transfer complex between the nicotinamide moiety of NAD+ and a
tryptophan residue in each protein. Barbieri et al.y(1989) and Cortina and Barbieri
(1989) have shown that Trp 26 is important for the efficient binding of NAD+ to
pertussis toxin suggesting that a similar charge transfer complex may exist within this
protein on binding of substrate.
Quenching of ~ 50% of the toxins intrinsic fluorescence occurred on titration
with NAD+ and Kd values of 43 |iM at 20°C, 28 pM at 30°C and 20 pM at 40°C
calculated. These values vPy'iL well with those determined by equilibrium dialysis at
the same temperatures, therefore confirming the results from this method.
5.3.4. The nature of the NAD+-binding site
Equilibrium dialysis and fluorescence demonstrated that there is one NAD+-
binding site per toxin molecule. NAD+ binds with a high affinity to pertussis toxin, the
Kd of 25 pM being of the same order of magnitude to those of diphtheria toxin (Kandel
etal,)1974) and Pseudomonas aeruginosa exotoxin A (Chung and Collier, 1977). Both
prokaryote and eukaryote ADP-ribosyltransferases (Moss etal. 1983; Gill, 1978) have
Kd values for NAD+ within the micromolar range, which would be as expected as the
normal cellular concentration of NAD+ is 70 - 100 pM (Gill, 1975).
It has been shown with cholera toxin, diphtheria toxin and exotoxin A, using
NAD+ analogues, that NAD+ binding involves recognition of the entire molecule with
the nicotinamide ring being especially important. A (3aPa secondary structure has been
predicted for cholera, diphtheria and E. coli. LT toxins (Duffy and Lai, 1986;
Yamamoto et al. 1984). This suggested that a Rossman fold of alternating a-helix and
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(3-sheet structure may make up the NAD+-binding sites of these proteins. This structure
represents the NAD+-binding sites of lactate dehydrogenase (Rossman et al.; 1974) and
other dehydrogenases. However, this predicted structure was disregarded after the X-
ray structure of exotoxin A found no such structure within this protein (Allured et al.;
1986) demonstrating that this protein did not contain a Rossman-fold type structure.
Whether this is the case with pertussis toxin or not also requires X-ray crystallographic
determination of its structure.
Binding of NAD+ to pertussis toxin results in the enzyme catalysed hydrolysis
of NAD+ producing nicotinamide and ADP-ribose. The nicotinamide-ribose linkage
must therefore be accessible to nucleophilic substitution by water. ADP-ribose is
subsequently accepted by Gi suggesting that there may be an appropriately placed
nucleophilic group on this protein. Tait and Nassau (1984), have suggested that the
active site of cholera toxin may comprise a hydrophobic pocket, which is responsible
for the efficient binding of substrate and a hydrophilic region associated with the site of
ADP-ribosylation. If this is the case with pertussis toxin then tyrptophan 26, along
with certain other residues within S-l, would constitute the hydrophobic binding pocket
of the protein. The SH-group on Gi which accepts the ADP-ribose reaction product
must also be recognised by the toxin, by the same mechanism as cysteine and the other
sulphydryl reagents are recognised.
More recently Locht etal (1990) have suggested that Cys 41 in S-l is located at
the NAD+-bnding site in a position close to at least one of the phosphates of NAD+.
The evidence for this was obtained from site-directed mutagenesis of Cys 41 and kinetic
analysis of the mutant proteins. Cys 41 was replaced with either serine, glycine,
proline or asparagine and finally with glutamate or aspartate. Replacement with serine
or glycine failed to abolish enzyme activity indicating that the sulphydryl group of Cys
41 is not essential for enzymic activity. No dramatic loss of activity was reported
following replacement of Cys 41 with proline or asparagine. This indicated that the
polarity of the side group at this location was not important, proline being non-polar and
asparagine being polar. These results really suggested that Cys 41 did not play a role in
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catalysis and that it was in fact either close to or within the NAD+-binding site. Finally
the introduction of a negative charge at position 41 abolished the NAD+-glycohydrolase
activity to 2% of the wild-type value. This dramatic effect suggested an electrostatic
repulsion between the negative charge within the protein and a negative charge with the
NAD+ molecule.
Cys 41 is located within the amino-terminal half of S-l and close to Trp 26.
Both of these residues are located between the two regions of high homology to cholera
toxin and E. coli. heat labile toxin A-subunits. Trp 26 and Cys 41 may therefore define
the NAD+-binding site with the aromatic ring of Trp 26 interacting with the
nicotinamide ring of NAD+. Further evidence for this theory can be gained from the
quenching of fluorescence data as this further implicates Trp 26 at the NAD+-binding
site.
Lochtetal (1990) proposed the model for the functional structure of pertussis
toxin S-l subunit shown in Figure 5.23. As shown this group proposes that the amino
terminal of S-l, which includes the two sequences of homology with cholera and L.T.
toxins as well as Cys 41 and Trp 26 may constitute the NAD+-binding site. The
carboxy terminal and the middle portions may be involved in G-protein binding and
finally Glu 129 may be important in catalysing the transfer of the ADP-ribose moiety
from NAD+ to the acceptor protein.
This is all very well, but the results from site-directed mutagenesis do not
necessarily prove that either Cys 41 or Trp 26 make up the NAD+-binding domain. The
effects on the kinetics of S-l after mutagenesis could result from a conformational
change induced by the mutation. The fact that NAD+ quenches the intrinsic
fluorescence of S-l does add further evidence to the participation of Trp 26 within the
NAD+-binding site. However, the fluorescence quench does not necessarily result as a
consequence of the interaction of NAD+ with this tryptophan but may perhaps form its
interaction of another within the amino-terminal of S-l. For these questions to be
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answered in full X-ray crystallographic analysis of the toxin must be undertaken. Only
then will a positive three-dimensional structure of the toxin and its constituent domains
be obtained.
FIGURE 5.23
PROPOSED MODEL FOR THE FUNCTIONAL STRUCTURE OF
PERTUSSIS TOXIN S-l.
























CROSS-LINKING OF PERTUSSIS TOXIN SUBUNITS
6.1. INTRODUCTION
The structure of pertussis toxin is discussed in section 1.2.3., however, as an
introduction to this chapter the model proposed to date is summarised. The overall
structure of this protein is the most complicated of the bacterial toxins discovered to
date, consisting of five different subunits, termed S-l through to S-5 on the basis of
their decreasing molecular masses, within the mature protein. Its molecular mass has
been the subject of much controversy in recent years with reported values ranging from
lOOkDa (Morse and Morse, 1976) up to 170kDa (Cowell et al,;1982). Tamura et al,
(1982) suggested that the molar ratios of subunits S-l, S-2, S-3, S-4 and S-5 within the
holotoxin was 1:1:1:2:1. This proposed stoichoimetry was based upon evidence from
the densitometric scanning of Coomassie blue stained polyacrylamide gels. This was
confirmed by Sekura et al. (1983) by the same method. However, in calculating this
stoichiometry both groups made the assumption that each subunit had an equal capacity
for Coomassie blue binding. This is very unlikely as dye binding is a property of the
overall charge of a protein, with more positively charged proteins binding more dye,
thus each of the toxin subunits should not bind dye at the same capacity.
Rappuoli and Nicosia (1987), demonstrated that in 2 M urea S-l is dissociated
from the B-oligomer complex. Further exposure of the B-oligomer to 5 M urea frees S-
5 from the remaining subunits leaving dimers, D1 of S-2 and S-4 and D2 of S-3 and S-
4. Finally exposure to 8 M urea causes all five subunits to dissociate. These subunit
associations are further evidence for the existence of two dimers within the holotoxin
and the 1:1:1:2:1 stoichoimetry.
The final piece of evidence for this model was derived from the nucleotide
sequence of the S-4 signal peptide. This leader sequence is forty two amino acids long,
being twice as long as that for any of the other subunits, and it has a high amino
terminal positive charge (Locht et al.( 1986; Nicosia et al.. 1986). Since the length of
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this peptide and the magnitude of its N-terminal positive charge are both important for
the efficient production of secreted proteins, it has been proposed that this signal peptide
may lead to the production of two S-4 subunits per toxin molecule.
All of the above evidence points to the existence of two molecules of S-4 within
the holotoxin. More recently Yamakawa etaL;(1990) have isolated pertussis toxin by
HPLC, and, on the basis of UV absorption again proposed the 1:1:1:2:1 stoichoimetry.
In this chapter I have discussed an alternative approach in the investigation of the toxin's
proposed stoichoimetry and into the geometry of the toxin subunits in space using the
methods of reversible cross-linking, two-dimensional gel electrophoresis and Western
blotting.
6,2. Cross-linking
Cross-linking involves the use of bifunctional chemical reagents which form a
number of intermolecular dimers, each of which contain a pair of neighbouring
subunits. As each subunit can form a linkage with one or more of its neighbours,
analysis of the subunits involved in each of the dimers should help to construct a map
showing the relative spatial location of each of the subunits within the assembled toxin.
This process is however further complicated as aggregates of more than two subunits
can be formed which, in a complicated system, can be difficult to analyse.
Bifunctional cross-linking reagents are used to analyse the tertiary structure of
proteins. These reagents modify amino acid side chains and are classified on several
criteria:
(a) the chemical specificity of the cross-linking reagent
(b) the length of the reagent
(c) whether the reagent cross-links the same amino acids (homobifunctional)
or different amino acids (heterobifunctional)
(d) whether the groups react chemically or photochemically
or (e) whether the reagents contain a cleavable internal bond.
Most of the bifunctional reagents modify lysine or cysteine residues. Cleavable
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reagents dithiobis (succinimidyl propionate), DSP and disuccinimidyl tartarate, DST,
were used to investigate the tertiary structure of pertussis toxin. Both of these reagents
are homobifunctional, being specific for primary or secondary aliphatic amines (Tesser
etal.^1975: Zarling et al. 1980) or N-terminal amines. The structures of both DSP and
DST are shown in Figure 6.1. Both reagents are cleavable. DSP contains an internal
disulphide bond and is cleavable with reducing reagents, DST is cleavable with
periodate. This cleavable linkage helps in the identification of the subunits involved in
each of these cross-linkages as cleavage of the reducib le bonds regenerate the original
monomelic subunits involved in each of the aggregates. This is very important for
pertussis toxin work, as, being such a complicated protein many dimers and larger
aggregates will be formed between the toxin subunits and analysis of their composition
will require this two-step process.
The simplest method of determining which subunits are involved in each
aggregate is by two-dimensional SDS polyacrylamide gel electrophoresis. This allows
separation of the cross-linked dimers, and aggregates of three or more of the subunits,
in the first dimension and then separation of the regenerated monomelic subunits in the
second dimension following cleavage of the cross-link bridge.
6.3. Two dimensional SDS polyacrylamide gel electrophoresis
The general two-dimensional SDS polyacrylamide gel electrophoresis system
employed for analysis of cross-linked pertussis toxin subunits is outlined in section
2.2.4.2, The cross-linking reagents DSP or DST were dissolved in a minimal amount
f )*/o V|v wi)
of DMSO, as they have limited water solubility, with water being added to give final
linker concentrations of 100 mM and 10 mM. The reagent was added to a 1 mg/ml
toxin solution and the reaction allowed to proceed in the cross-linker/solvent emulsion.
The reaction is favoured by alkaline pH which maintains the amine group in an
unprotonated state. Experiments were performed in phosphate buffered saline at pH
8.3 and cross-linking reagent was added to the toxin solutions to a final concentration of
1-10 mM reagent. The emulsion was incubated at room temperature for 4 hours.





















THE STRUCTURES OF THE CROSS-LINKING REAGENTS
USED FOR STRUCTURAL STUDIES OF PERTUSSIS TOXIN
SUBUNITS.
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first dimension 5% (w/v) - 20% (w/v) or 10% (w/v) - 20% (w/v) acrylamide linear
gradient gels under denaturing conditions. Strips from the first dimension were then
excised, the cross-linkage reduced, and the monomelic subunits resolved on a second
dimension 17.5% (w/v) acrylamide gel.
6.4. RESULTS
6.4.1 Two dimensional SDS polyacrylamide gels
Figure 6.2 shows a 5% - 20% (w/v) acrylamide gradient first dimension SDS
polyacrylamide gel of DSP cross-linked subunits. The molecular masses of the cross-
linked species formed were determined by comparison with standard proteins of known
mass and by comparison with the molecular mass of individual pertussis toxin subunits.
As the molecular masses of the toxin subunits are known to great accuracy these were
thought to be acceptable molecular mass standards. The mass of the cross-linked
species calculated from this gradient are shown in Table 6.1. However this gradient
does not separate the lower molecular mass species very well and a 10% - 20% (w/v)
acrylamide first dimension gel was next employed. Figures 6.3 and 6.4 show the
separation of both DSP and DST cross-linked species obtained from this gradient.
Again, the molecular masses of these cross-linked aggregates were determined and are
shown in Table 6.1. The masses of the aggregates obtained with the DSP cross-linker
suggests that S-l has formed dimers with both subunits S-2 and S-3 and that S-4 has
formed aggregates with S-2 and S-3.
The shorter, DST cross-linker, shows a different pattern of dimer formation, the
calculated masses again being shown in Table 6.1.
FIGURE 6.2
5% - 20% (w/v) ACRYLAMIDE SDS POLYACRYLAMIDE GEL
OF PERTUSSIS TOXIN AND CROSS-LINKED PERTUSSIS
TOXIN SUBUNITS.
LANE 1 low molecular weight markers
LANE 2 lOmM DSP cross-linker incubation
LANE 3 Pertussis toxin standard
LANE 4 high molecular weight markers
/
FIGURE 6.3
10% - 20% (w/v) ACRYLAMIDE SDS POLYACRYLAMIDE GEL
SHOWING SEPARATION OF CROSS-LINKED AGGREGATES.
LANE 1 Pertussis toxin standard
LANE 2 ImM DST in final reaction mixture
LANE 3 ImM DST in final reaction mixture
LANE 4 lOmM DST in final reaction mixture
LANE 5 lOmM DST in final reaction mixture
LANE 6 lOmM DSP in final reaction mixture
LANE 7 lOmM DSP in final reaction mixture



















FIRST DIMENSION 10% - 20% (w/v) ACRYLAMIDE SDS
POLYACRYLAMIDE GEL OF CROSS-LINKED SPECIES.
LANE 1 lOmM DSP in final reaction mixture
LANE 2 ImM DSP in final reaction mixture
LANE 3 lOmM DST in final reaction mixture
LANE 4 ImM DST in final reaction mixture
LANE 5 Pertussis toxin standard
LANE 6 high molecular weight markers
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TABLE 6.1 Estimated molecular masses of the cross-linked
aggregates from the first-dimension gradient
SDS polyacrylamide gel
5% - 20% gel
DSP cross-linker
10% - 20% gel
DSP cross-linker
10% - 20% gel
DST cross-linker






The calculated mass of each of the aggregates gives an idea of which subunits
are involved in each of them, but because of the large number of possible dimers and
aggregates of two or more subunits which could be formed, it is impossible to
positively determine the composition of each. This is further complicated as the
molecular mass of S-2 is almost identical to that of S-3 and they are both very close to
the mass of S-l, with the mass of S-4 also being very similar to that of S-5. Thus the
combined mass of two or more of these subunits, in many different combinations of the
individual monomers, would result in an overall mass which could correspond to
several individual combinations. This being the case a second dimension
electrophoresis is essential to confirm which of the subunits are involved in each of the
cross-linked combinations. Regeneration of the monomelic subunits is the first step in
this two dimensional system, with the individual subunits being exposed on the second
dimension SDS polyacrylamide gel.
Several forms of second dimension were attempted. Firstly, a strip was cut
from the first dimension gel and soaked in a reducing buffer for 2 hours. This buffer
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was 20 mM Tris, pH 6.7 containing 3 mM DTT (Brennen et al 1985), the reducing
reagent presumably cleaving the internal disulphide bond of DSP. The strip was then
turned through 90° and fixed to the top of a second dimension 17.5% (w/v) acrylamide
separating gel for electrophoresis in this dimension (Zarling et al. 1980: Takada et al ^
1984). None of the cross-linked species were dissociated into subunits by this method
and each of the aggregates lies on the diagonal. Figure 6.5 shows a typical second
dimension gel obtained from this method.
Reduction within the gel matrix itself was the technique next tried. 5 mM
dithiothreitol was incorporated firstly within both the stacking and separating gel
matrices and secondly within the stacking gel alone. Neither of these methods produced
results which could confirm the predictions from the first dimension. Incorporation of
thiol within both gel matrices produced gels which could not be interpreted. This was
probably due to the presence of reducing reagent within the separating gel matrix as it
had been previously demonstrated (Sekura et ak l983) that pertussis toxin subunits
separate differently under reducing conditions. Sekura et al.^1983) demonstrated that
under reducing conditions the electrophoretic mobilities of the S-4 and S-5 subunits
were reversed and that S-2 and S-3 co-migrate, making the identification of the subunits
even more difficult. With this in mind the second attempt at reducing the cross-linkages
within the gel matrix was carried out, but this time dithiothreitol was incorporated
within the stacking gel matrix alone. The proteins from the first dimension strip were
run into this stacking gel and once the aggregates were within the matrix the current was
switched off for a 2 hour period. The cross-linker would presumably be cleaved during
this time and once the current was reapplied, the regenerated monomelic subunits would
be separated within the 17.5% (w/v) acrylamide resolving gel. This method was the
most successful of the two dimensional systems employed. Figure 6.6 shows a typical
gel obtained from this technique. Some of the cross-links have certainly been reduced
within the second dimension, and it is possible to identify the subunits involved within
the proposed S-l and S-2 and S-l and S-3 dimers. However, as before the gel system
did not give a clear picture of the subunits involved in each dimer.
As a final attempt at a two dimensional gel electrophoresis system, electroelution
FIGURE 6.5
SECOND DIMENSION 17.5% (w/v) ACRYLAMIDE SDS
POLYACRYLAMIDE GEL SHOWING SEPARATION OF
SUBUNITS S-l, S-2, S-3, S-4 AND S-5 AND CROSS-LINKED
AGGREGATES.
THE GEL SHOWS THAT NONE OF THE CROSS-LINKED
AGGREGATES WERE REDUCED INTO THEIR NOMOMERIC






SECOND DIMENSION 17.5% (w/v) ACRYLAMIDE SDS
POLYACRYLAMIDE GEL, WITH lOmM DTT WITHIN THE
STACKING GEL MATRIX.
THE GEL SHOWS DIAGONAL SEPARATION OF S-l, S-2, S-3,
S-4 AND S-5 AND THE REDUCTION OF SOME CROSS-
LINKED SUBUNITS.
THE GEL IS VERY DIFFICULT TO INTERPRET AND POSITIVE
DETERMINATION OF THE SUBUNITS INVOLVED IN EACH
LINKAGE WAS NOT POSSIBLE.
S-4S-5
158
of the cross-linked species from the first dimension gradient was tried. The cross-
linked aggregates were again separated on a first dimension 10% - 20% (w/v)
acrylamide gradient SDS polyacrylamide gel. A portion of this gel was fixed and silver
stained with the bands corresponding to the aggregates of interest being cut from the
remainder of the gel. The strips were cut into 1cm x 2mm portions and the proteins
electroeluted from the gel using an ISCO apparatus. The buffer used for electroelution
was 10 mM potassium phosphate, pH 7.5, 1 M urea and a current of 30 mA for 4 hours
was applied to the system.
The concentrated aggregates were reduced with 0.1% (v/v) mercaptoethanol and
boiled in 0.1% (w/v) SDS for 5 minutes before being applied to a second dimension.
This method again proved unsuccessful as insufficient protein was eluted from the first
dimension to produce a conclusive pattern of monomelic subunits within the second
dimension. The problem of the electrophoretic mobilities of the individual subunits
under reducing conditions also further complicated analysis of the second dimension
gels. Further to this, once sufficient protein had been concentrated from a number of
first dimension gels, the silver stained second dimension gels were poorly resolved,
with very high background staining, again giving no conclusive results. It was obvious
that an alternative approach was necessary to confirm the predictions, based on
molecular mass analysis, of which subunits are present in some of the dimers.
6.4.2. Western blotting.
Cross-linked species were again separated on a 10% - 20% (w/v) acrylamide,
SDS polyacrylamide gel. Strips from these gels were removed and the proteins
transferred onto nitrocellulose by the method of Towbin et al (1978). The antibodies
used were antipeptide antibodies raised against synthetic peptides derived from the
amino acid sequence of either S-l, S-2 or S-3 by Richard Seabrook at CAMR, Porton
Down (Seabrook, et al 1990). Horseradish peroxidase conjugated anti-mouse IgG was
the second antibody and the bands were visualised by 4-chloro,2-naphthol and
hydrogen peroxide. The blotting results are shown in Figure 6.7. These confirm the
results previously proposed with the DSP cross-linker (insufficient antibody being
FIGURE 6.7
WESTERN BLOTTING ANALYSIS OF DSP CROSS-LINKED
SUBUNITS.




























STRIPS 2 AND 3 SHOW THAT THE S-2 ANTIBODY CROSS-
REACTS WITH SUBUNIT S-3 AND THAT THE S-3 ANTIBODY
CROSS-REACTS WITH SUBUNIT S-2 WHICH IS NOT
SURPRISING DUE TO THE HIGH DEGREE OF HOMOLOGY
BETWEEN THE TWO SUBUNITS.
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available to Western blot the DST linker strips). Strip one shows the S-l antibody
recognition with subunit S-l and two cross-linked aggregates being identified. Strip
two shows the S-2 results, again showing the S-2 subunit and the recognition of two
cross-linked aggregates. It is important to note that one of the S-2 cross-linked bands is
the same as one recognised by the S-l antibody. The final strip is the results from the
S-3 blot. Again two aggregates were recognised with one of the bands being at the
same position as the second of the S-l aggregates.
These results confirm the predicted dimer formation between subunits S-l with
both subunits S-2 and S-3 and show that subunit S-4 or S-5 has also formed dimers
with subunits S-2 and S-3. On the basis of molecular mass these second dimers are
more likely to be S-2/S-4 and S-3/S-4 dimers, but an S-4 antibody blot would be
needed to confirm this 100%, and this was not available.
6.5. DISCUSSION
This chapter has discussed an alternative approach in the investigation into the
spatial arrangement of pertussis toxin subunits, namely reversible cross-linking
reagents, two-dimensional gel electrophoresis and Western blotting.
6.5.1 Cross-linking and two-dimensional SDS polyacrylamide gel
electrophoresis
The two cross-linking reagents used; dithiol (succinimidyl proponate) -
DSP and disuccinimidyl tartarate, DST, were both specific for primary and secondary
aliphatic amines and produced a reproducible pattern of aggregate formation on a first-
dimension 10-20% (w/v) acrylamide SDS polyacrylamide gel. The molecular mass of
each of the aggregates were calculated by comparison of their mobilities within these
gels to the electrophoretic mobilities of a standard set of proteins and also with the
electrophoretic mobilities of the individual toxin subunits, whose masses are known
precisely from the derived amino acid composition from their DNA sequences. The
molecular mass of each aggregate gave a good idea of which subunits were included
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within each conjugate. These primary observations obviously needed to be confirmed
due to the large number of possible constructs which could be formed, many of which
would have similar masses. Confirmation was hoped to result from the second-
dimension separation of the regenerated monomelic subunits contained within each of
the aggregates. The 12 A DSP cross-linked aggregates were never sufficiently reduced
after soaking gel strips in a reducing buffer to enable the monomelic subunits to be
identified within the second-dimension, and incorporation of thiol within the gel
matrices caused added complications to the two-dimensional system, as the toxin
subunits run differently under reducing conditions.
None of the many attempts at a two-dimensional system produced gels that
confirmed the predictions made from the first-dimension gel. Reduction of the internal
disulphide bond within DSP was not achieved, a possible explanation for this could be,
that the cross-linked subunits formed very tightly associated aggregates, shielding the
disulphide bond from attack with reducing reagents thus preventing the regeneration of
the monomelic units. The few results which emerged from the second-dimension gels
were consistent with those proposed from the first-dimension, but these results were
not conclusive.
6.5.2. Western blotting
As the two-dimensional SDS polyacrylamide gel system did not yield conclusive
results on the geometry of the individual toxin subunits, an alternative approach for
determining the composition of each of the dimers was necessary. Western blotting was
the obvious direction to proceed and antipeptide antibodies against subunits S-l, S-2
and S-3 were employed. These were used to blot nitrocellulose strips of transferred
DSP cross-linked subunits. This proved very successful and by comparison with the
calculated molecular masses from the first-dimension it was possible to construct a map
showing the relative spatial locations of some of the toxin subunits at 12 A resolution.
DSP cross-linked dimers were formed between subunit S-l with both subunits S-2 and
S-3 and between S-4 with both subunits S-2 and S-3. These results are summarised in
Figure 6.8. The antibodies did not react with any of the higher molecular mass
FIGURE 6.8
PROPOSED GEOMETRY OF PERTUSSIS TOXIN
SUBUNITS AT 12A RESOLUTION
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aggregates, this perhaps being due to their combined conformations preventing
recognition by each of the antipeptide antibodies.
The cross-linked results obtained so far provide further evidence for the
existence of two dimers, D1 of subunits S-2 and S-4 and D2 of subunits S-3 and S-4,
within pertussis toxin (Tamura etal>;1982; Sekura etal.^1983; Rappuoli and Nicosia,
1987). However an S-4 immunoblot would have been useful to confirm this. Based
on these results the cross-linking data also suggests that S-l may sit on a plane, elevated
above the B-oligomer subunits in a similar conformation to that previously proposed for
cholera toxin (van Heyningen, 1982). S-2 and S-3 may surround S-l in such a way as
to protect it from interaction with the host-cell membrane on binding to and entering into
the host cell. No aggregates have, as yet, been identified which involve S-5. This
suggests that the other subunits may surround S-5 in such a manner as to protect it from
the action of the cross-linkers.
In summary the evidence so far obtained from cross-linking confirms the
stoichiometry proposed previously by other workers. There is a great deal more work
to be done using cross-linkers, involving those of different lengths and amino acid
specificities. Once this task has been undertaken a map showing the precise overall
subunit arrangement within the holotoxin should be possible, this geometry being
confirmed once the toxins crystal structure has been elucidated.
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CHAPTER 7
SUMMARY AND FUTURE WORK
The work completed for this thesis has served to characterise pertussis toxin
further on the basis of its enzymic activities and overall subunit conformation.
Firstly the toxin's enzymic activity was investigated and a Michaelis constant,
Km value, of (30 ± 5[iM) and a kcat value derived. These values were in close
agreement with those already published, (Tamura et al,1982: Moss and Vaughn, 1984;
Burns et aL 19861. when the assay conditions involved 250mM dithiothreitol. It had
been previously demonstrated that by increasing the concentration of sulphydryl
reagent within the assay protocol, even to the incredibly high concentration of 250mM,
that increasing amounts of nicotinamide were released. This effect was further
investigated on the theory that these reagents were acting not only as activating
reagents but also as substrates for this enzyme catalysed reaction.
An HPLC system was devised which separated the reaction products and by
using radioactively labelled 14C-cysteine and ^H-NAD+, the label being on the
ADP-ribose moiety of this molecule, a reaction product was isolated containing the
carbon atoms of the sulphydryl reagent and the ADP-ribose group of NAD+. The
following reaction was proposed, with a Km of 105mM determined for cysteine in
saturating NAD+ -
NAD+ + cysteine > ADP-ribosyl-cysteine + Nicotinamide
The high Km value calculated for cysteine illustrates why 250mM dithiothreitol
had previously been included within the reaction mixture for maximum nicotinamide
production. West et al.. (19861 have shown that it is a cysteine residue within Gi which
accepts the ADP-ribose moiety from pertussis toxin catalysed ADP-ribosylation, the
sulphydryl group within the NAD+-glycohydrolase reaction must be acting in an
analogous fashion.
The binding affinity of NAD+ for pertussis toxin was determined using
equilibrium dialysis and quenching of the proteins intrinsic fluorescence upon titration
with ligand. Equilibrium dialysis involved the direct quantitation of free and bound
ligand, and is the simplest method of calculating binding parameters. Kd, the
equilibrium dissociation constant, and n, the maximum number of moles of substrate
bound per mole of protein. Kd values were obtained at a range of temperatures and an
estimate of the enthalpy change on binding of NAD+ to the toxin derived. This value
of 30k Joules.moT1 is typical of such an interaction. The number of binding sites on
the toxin for NAD+ was shown to be one, which was as we would expect as it was
unlikely that the toxin should have evolved different binding sites for NAD+ in order to
(XcKvd
catalyse essentially the same reactions of ADP-ribosylation and NAD+-glycohydrolase/x
Fluorescence is an indirect method of determining ligand-binding constants. It
utilises the fact that a tryptophan residue within S-l is involved in the NAD+-binding
site and that the intrinsic fluorescence of the protein is reduced on binding of NAD+.
The Kd value derived from this method is in close agreement with that from
equilibrium dialysis and both are of the same order of magnitude as the Km for the
toxin catalysed NAD+-glycohydrolase activity, which is again as we would have
assumed.
It would be interesting to repeat the above work using the isolated active subunit
in order to show whether its kinetics are the same as those of the holotoxin. In order
to do this a suitable system for separating sufficient S-l must be devised as the protein
concentration required for equilibrium dialysis is >1.0 mg/ml to enable accurate
calculation of free and bound ligand.
It would also be interesting to investigate the binding affinities of nucleotides,
such as ATP and GTP, for pertussis toxin. These ligands have been shown to bind
specifically to the toxin and in doing so reduce the affinity of S-l for the B-oligomer, a
step essential for the entry of S-l within the eukaryotic cell (Burns et al 1987; Burns
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1988).
The final piece of work undertaken in this project yielded rvtutV\ information on
the tertiary structure of pertussis toxin. The two cross-linking reagents used, DSP and
DST, demonstrated which subunits were in close association with each other and these
results were confirmed using monoclonal antibodies to S-l, S-2 and S-3. The cross-
linking data showed that S-l is in close association with both subunits S-2 and S-3.
No cross-linkages were identified between S-l and the other two subunits showing
that they are not accessible to linkage with the reagents used. This suggests that S-l
may be on a plane above the B-subunits, shielding S-4 and S-5, with only S-l and S-2
being accessible to the cross-linking reagents. S-4 produced dimers with both S-2 and
S-3 showing that these subunits are in close association and providing more evidence
for the existence of two dimers within the assembled molecule.
Future work on cross-linking would concentrate on DST, the shorter of the two
cross-linkers. As this linker is periodate cleavable a reproducible two-dimensional
system may be possible as there is no reducing reagent required which would
complicate analysis of the results, the toxin subunits running differently in reducing
and non-reducing conditions. Once results have been collected from this it is hoped
that a three-dimensional map of the spatial localisation of the subunits would be
possible. The results from the cross-linking studies will hopefully be confirmed once
the crystal structure of the toxin has been deduced. Crystals of the toxin have been
grown by Stella Fawcett at Edinburgh and are presently undergoing X-ray analysis on
a grant supported by the Medical Research Council.
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APPENDIX
A1 Further binding at 7°C
A 2 Further binding at 20°C
A 3 Further binding at 23°C
A 4 Further binding at 30°C
A 5 Further binding at 40°C
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